BACK TO QUICK LINKS AGENDA SPEAKERS EMERGING COMPANIES START-UP COMPANIES SPONSOR PROFILES FLOOR PLAN ATTENDEES QUICK LINKS EXHIBITORS
BACK TO QUICK LINKS THANK YOU TO OUR SPONSORS THANK YOU TO OUR SUPPORTING PARTNERS
1 BACK TO QUICK LINKS Welcome to BioNJ’s 2024 BioPartnering Conference, On behalf of BioNJ, J.P. Morgan, Johnson & Johnson and Morgan Lewis, it is our honor to welcome you to the Fourteenth Annual BioPartnering Conference, “Connecting Innovators, Investors and Industry.” This event brings together entrepreneurs, executives, investors, collaborators and BD professionals from the life sciences industry for networking, 1-1 partnering (both in-person and virtual), company pitches, exhibits and plenary sessions. The dynamic agenda is crafted to cultivate fruitful partnerships, forge impactful opportunities, nurture the ecosystem and advance medical innovation. We extend our gratitude to our judges, reviewers, coaches, exhibitors, partners and sponsors for their exceptional support. Special thanks to our industry experts leading plenary discussions and the valuable Industry Connection Desks, as well as the BioPartnering Conference Planning Team for their dedication in bringing this vision to life. We are thrilled to welcome the record number of emerging and early-stage companies presenting their new innovations and technologies at the conference. We are grateful for Jersey City Economic Development Corporation’s support in bringing this important event to the Liberty Science Center. We are delighted to have Mayor Steven M. Fulop of Jersey City and Paul Hoffman, President and CEO of Liberty Science Center and SciTech Scity, at the Conference. We hope you come away from the Conference with new collaborations, partnerships and inspiration that will lead to future innovation. Thank you for being here. Because Patients Can’t Wait®, WELCOME Debbie Hart President & CEO BioNJ David C. Schwartz, J.D. Partner Morgan Lewis Samuele Butera, MPP President, US Pulmonary Hypertension & Retina The Janssen Pharmaceutical Companies of Johnson & Johnson Kathleen Addison Executive Director Life Sciences J.P. Morgan
2 BACK TO QUICK LINKS CONFERENCE AGENDA Tuesday, May 14, 2024 Time Session 7:30 a.m. – 8:15 a.m. Governor’s Hall Breakfast & Networking Welcome to the BioPartnering Conference! Please enjoy breakfast while networking with other attendees! 8:20 a.m. – 8:45 a.m. Governor’s Hall Welcome & Opening Remarks • Debbie Hart, President & CEO, BioNJ • Jersey City Mayor Steven Fulop • Samuele Butera, MPP, President, U.S. Pulmonary Hypertension & Retina, Johnson & Johnson & Vice Chair, BioNJ • Steven M. Cohen, J.D., Partner, Morgan Lewis • Alma DeMetropolis, CFA, CFP, Managing Director & Market Manager, J.P. Morgan Private Bank 8:45 a.m. – 9:15 a.m. Governor’s Hall Industry Overview: Key Trends & Outlook • Sophie Jones, M.D., Managing Director, J.P. Morgan, Healthcare Investment Banking 9:20 a.m. – 9:50 a.m. Governor’s Hall Panel: BioPartnering: Keys to Success for Biotech and Pharma Partnerships Our panel of experts will discuss the importance of partnering in today’s life sciences landscape, highlighting key components of effective partnering agreements and identifying potential warning signs for emerging companies. Panelists: • Dov Hass, J.D., Vice President, Head, Genetic Medicine Business Development, Regeneron Pharmaceuticals • Alan Leeds, J.D., Partner & Co-Leader, Global Life Sciences Practice, Morgan Lewis Partner • Phil Tinmouth, MBA, Chief Business Officer, Mammoth Biosciences Moderated by: • Laurie Burlingame, J.D., Partner, Morgan Lewis 9:55 a.m. – 10:25 a.m. Governor’s Hall Panel: How Biopharma Companies are Using AI to Accelerate Innovation Discover how biopharma leaders leverage cutting-edge artificial intelligence technologies to propel innovation forward at an unprecedented pace. Gain insights into the strategic integration of AI across the drug discovery, development and commercialization processes. Panelists: • Tyler Bryk, Head, Artificial Intelligence, PTC Therapeutics • Bill Comtois, Associate Partner, IBM • Hal Stern, Chief Information Officer, Innovative Medicine R&D, Johnson & Johnson Moderated by: Kim Cato, MBA, Vice President, Information Technology, CCG Thermo Fisher Scientific
3 BACK TO QUICK LINKS CONFERENCE AGENDA Time Session 10:30 a.m. – 5:30 p.m. 2nd & 3rd Floors 1:1 Partnering Meetings 10:30 a.m. – 10:45 a.m. PSEG Court Break: Refreshments, Networking, Exhibits 10:50 a.m. – 12:10 p.m. Lower Level Classrooms and Interactive Theater Company Pitch Presentations: Session 1 12:15 p.m. – 1:15 p.m. Governor’s Hall Networking Lunch Remarks by: Paul Hoffman, President & CEO, Liberty Science Center 1:00pm – 4:00pm PSEG Court Industry Connections Desks Open Pre-scheduled appointments. Meet at the Registration Desk. 1:20 p.m. – 2:30 p.m. Lower Level Classrooms and Interactive Theater Start-up Pitch & Company Pitch Presentations: Session 2 2:35 p.m. – 2:55 p.m. PSEG Court Break: Refreshments, Networking, Exhibits 3:00 p.m. – 4:10 p.m. Lower Level Classrooms and Interactive Theater Start-up Pitch & Company Pitch Presentations: Session 3 4:15 p.m. – 4:45 p.m. Governor’s Hall Venture Capital’s New Era: Dynamic Shifts and Future Trends This session will delve into the criteria that venture capitalists consider when evaluating businesses, particulary in the current funding environment. The panel will discuss factors such as leadership, strategic alignment, proof of concept, detailed capital utilization plans, and the size of the accessible market. Panelists: • Nancy Ondovik, MBA, Pharm.D., Principal, New Company Creation, Johnson & Johnson • Jenna Hebert, Ph.D., Senior Venture Associate, RA Capital • Jim Gunton, MBA, Managing Partner & Founder, Tech Council Ventures Moderated by: • Emilio Ragosa, J.D., Managing Partner, DLA Piper 4:45pm – 5:00 p.m. Governor’s Hall Closing Remarks & Company Presentation Awards Ceremony 5:00 p.m. – 6:00 p.m. Reception 3rd Floor Networking Cocktail Reception
4 BACK TO QUICK LINKS SPEAKERS Tyler Bryk Head, Artificial Intelligence PTC Therapeutics Empowering people to use AI responsibly is what drives Mr. Bryk. The AI & Machine Learning Team, led by Mr. Bryk, strives to create innovative AI solutions that aid in delivering best-in-class biotech, with a core focus being on AIenhanced drug discovery, and clinical trial optimization. Throughout his journey at PTC, Mr. Bryk has paved the way for others aspiring to be leaders in the AI space. He has played a part in numerous initiatives, including his most recent endeavor of creating PTC’s Responsible AI Committee, which brought together a group of cross-functional executives to discuss and promote the ethical use of AI. Samuele Butera, MPP President, U.S. Pulmonary Hypertension & Retina, Johnson & Johnson Vice Chair, BioNJ As President of Pulmonary Hypertension and Retina Gene Therapies in the U.S., Mr. Butera is dedicated to supporting rare disease Patient populations and responsible for leading this therapeutic area through the continued advancement of key brands and preparing future pipeline launches. With a proven track record in delivering global healthcare innovation and business leadership, Mr. Butera’s goal is to bring transformational solutions to Patients, providers and healthcare systems around the world. Previously, Mr. Butera held global leadership roles at Janssen and Novartis, following international experiences at McKinsey & Company, Goldman Sachs and the United Nations. Kim Cato, MBA Vice President, Information Technology CCG, Thermo Fisher Scientific Ms. Cato is a strategic-thinking executive with more than 20 years of experience in the IT industry. She is a motivated achiever partnering with executive management teams in developing and executing dynamic, enterprise-level business strategies and start-up initiatives providing competitive advantages and delivering business outcomes. Prior to joining Thermo Fisher, Ms. Cato was Senior Director at Whirlpool Corporation and CIO for GPS Supply Chain at GE Power. She spent four years at Whirlpool and eight years at GE in a number of IT leadership roles supporting infrastructure and enterprise applications, business initiatives, engineering, product development, supply chain and analytics platforms. Steven M. Cohen, J.D. Partner Morgan Lewis Mr. Cohen represents entrepreneurs, private equity investors and venture capital funds. He advises clients in such industries as technology, life sciences, chemicals, consumer products, digital health and fintech. Mr. Cohen counsels midAtlantic region investors and emerging growth companies in a variety of business transaction including equity financing transactions, mergers and acquisitions, divestitures, initial public offerings, joint ventures and international strategic partnerships. He is the former chair of the firm’s emerging companies and venture capital practice. Laurie Burlingame, J.D. Partner Morgan Lewis Laurie A. Burlingame has a diverse practice representing clients on a broad spectrum of transactions in the life sciences and technology industries, including initial and follow-on public offerings, venture capital financings, deSPAC transactions, and mergers and acquisitions (M&A). She regularly serves as outside general counsel to clients, advising management teams and boards of directors on a variety of matters throughout the lifecycles of various companies, including formation and founder issues, licensing transactions, strategic collaborations, commercial transactions, corporate governance, disclosure requirements, and other general corporate matters.
5 BACK TO QUICK LINKS SPEAKERS Alma DeMetropolis, CFA, CFP Managing Director & Market Manager, J.P. Morgan Private Bank Ms. DeMetropolis brings more than 30 years of financial experience to advise families, business owners, executives and endowments and foundations. She provides executive guidance across the firm’s lines of business within the State and is instrumental in driving community and employee engagement. Ms. DeMetropolis began her career as a Risk Analyst at J.P. Morgan in 1992. Since then, she has held several global roles and spent seven years on foreign assignments in Latin America and Europe. Steven Michael Fulop Mayor Jersey City Steven Michael Fulop is the 49th Mayor of Jersey City – the most diverse city in the nation and the soon-to-be largest city in New Jersey. Since Mayor Fulop took office in 2013, residents have seen seven consecutive years of stable taxes, over 300 new police officers hired, 1,500 units of affordable housing built, expanded recreation, nearly $10 million invested in parks and open space and roughly 800 small businesses opened creating approximately 10,000 new jobs. Mayor Fulop has led the city to record economic development that’s benefited families of all income levels. Jim Gunton, MBA Managing Partner & Founder Tech Council Ventures Mr. Gunton has invested in privately-held growth technology companies for over 20 years. Before co-founding the $80 million NJTC Venture Fund in 2001, he was a partner at Edison Venture Fund and a manager at Oracle Corporation in Silicon Valley. Mr. Gunton served formerly as the National Association of Small Business Investment Companies (NASBIC) governor. He has also served on the board of numerous private and public companies, including Achieve3000, Amber Road, CytoSorbents, InstaMed and IntegriChain. Debbie Hart President & CEO BioNJ Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in 1994. Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a respected thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become the trusted voice of the life sciences industry in New Jersey – working directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and Patient access, while ensuring health equity and healthcare affordability. Most recently, she was named by Governor Murphy as the Chair of the New Jersey Commission on Science, Innovation and Technology. Bill Comtois Associate Partner IBM Mr. Comtois leads the Strategy and Process Transformation practice for Generative AI and Automation enterprise solutions. His current focus is on biopharma, med tech and healthcare companies. Mr. Comtois and the teams he leads deliver leading-edge transformative solutions using GenAI large language models, autonomous multi-agent frameworks and leading governance techniques for use cases including report generation and publication for regulatory submissions, intelligent copilots for process and data discovery, pharmaceutical product labeling, sustainability management for supply chains, prior authorization of medical procedures, and medical device product life cycle management.
6 BACK TO QUICK LINKS Paul Hoffman President & CEO Liberty Science Center Mr. Hoffman is President and CEO of Liberty Science Center, the most visited cultural institution in New Jersey and the largest science learning center in the NYC metropolitan area, with an annual attendance exceeding 750,000. He leads SciTech Scity, LSC’s partnership with Jersey City, the State of New Jersey, and Hudson County to create a “Science City of Tomorrow,” a 30-acre innovation campus to launch and grow world-changing science and technology start-ups and reimagine public-school STEM education. Sophie Jones, M.D. Managing Director J.P. Morgan, Healthcare Investment Banking Dr. Jones advises Boards and executive management teams of innovative life sciences companies across a wide range strategic and financing opportunities, including capital formation and mergers & acquisitions. Prior to J.P. Morgan, she worked at Centerview Partners, and has advised on over $250 billion in transactions. Prior to her career in investment banking, Dr. Jones was a surgeon trained in general surgery and heart and lung transplant at Columbia University/New York-Presbyterian Hospital. While at Columbia, she served as Chief Fellow and as the Resident representative to the Board of New York-Presbyterian Hospital’s House Staff Quality Council. SPEAKERS Pavita Howe Vice President, Innovation & Entrepreneurship BioNJ Ms. Howe is an entrepreneurial leader with experience in business development, marketing, strategy, program management, new products, launches, business planning and building ecosystems at start-ups, academic institutions and large organizations. Most recently, she served as Director of Entrepreneurship Partnerships at Rutgers University, where she worked with internal and external partners to grow Rutgers’ entrepreneurial ecosystem, bring visibility to Rutgers affiliated start-ups, and connect them to valuable resources at the university and across the broader New Jersey entrepreneurial network. Jenna Hebert, Ph.D. Senior Venture Associate RA Capital Dr. Hebert is a Senior Associate on the Venture Team at RA Capital Management, a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life sciences companies. She focuses on identifying and diligencing opportunities for early-stage investments and advises RA’s portfolio companies. Dr. Hebert currently serves as a board observer for Expansion Therapeutics, Alchemab Therapeutics and Typewriter Therapeutics. Prior to RA, Dr. Hebert was an Analyst and Medical Writer at Costello Medical Consulting. Dov Hass, J.D. Vice President, Head, Genetic Medicine Business Development Regeneron Pharmaceuticals Mr. Hass is Vice President, Head of Genetic Medicine Business Development for Regeneron Pharmaceuticals. His remit is portfolio and technology strategy, sourcing, evaluation and transactional ideation and execution of strategic transactions, including in-licensing, out-licensing, collaborations and M&A for genetic medicines and neuroscience. Prior to his current role, Mr. Hass practiced corporate law for almost 15 years as a life sciences corporate and transactional lawyer.
7 BACK TO QUICK LINKS Alan Leeds, J.D. Partner & Co-Leader, Global Life Sciences Practice Morgan Lewis Leading the firm’s life sciences transactions practice and a co-leader of the firm’s Global Life Sciences Industry Team, Mr. Leeds represents life sciences companies from early stage biotechnology start-ups to global pharmaceutical companies, as well as specialty pharma, medical device and other technology companies. He also works with venture capital firms that focus on the life sciences industry. Mr. Leed’s practice includes negotiating and structuring strategic alliances and other complex collaborations, corporate partnering arrangements, licensing transactions, acquisitions and divestitures, manufacturing and supply agreements, distribution arrangements, co-promotion arrangements and joint ventures. Nancy C. Ondovik, MBA, Pharm.D. Principal, New Company Creation Johnson & Johnson Ms. Ondovik is responsible for supporting the creation and launch of newly defined companies aligned with the strategic needs of Johnson & Johnson’s business sectors. She has a passion for finding innovation through external investments and collaborations and has a long track record of negotiating complex transaction agreements. Prior to her current role, Ms. Ondovik served as Senior Director, Transactions in support of the Cardiovascular, Metabolism & Retina Therapeutic Area and was responsible for leading the evaluation, negotiation and execution of numerous business development transactions. Emilio Ragosa, J.D. Managing Partner DLA Piper Mr. Ragosa counsels clients on securities offerings, mergers and acquisitions and venture capital transactions. He also advises on corporate transactions ranging from seed financings, venture financings and private placements to public offerings. Mr. Ragosa’s clients include private and public companies, as well as venture capital firms and underwriters. His experience makes him uniquely capable of advising clients from formation through capital raising until a sale or IPO. Within the technology industry, Mr. Ragosa has experience with digital media, financial services technology, e-commerce and health care IT. Within the life sciences sector, his experience includes biotechnology, medical devices and specialty pharmaceuticals. Hal Stern Vice President & Chief Information Officer, Innovative Medicine R&D Johnson & Johnson Mr. Stern’s Team designs and delivers end-to-end systems to support discovery, early development, clinical development, regulatory, safety and quality processes. Mr. Stern has a strong interest in data science, non-traditional and applied computing techniques, security, privacy, large-scale networking, intellectual property management. He joined Johnson & Johnson from Merck & Company, where he was AVP, Merck Research Labs Engineering. Before joining Merck, Mr. Stern had a 25-year career in the technology industry, with variety of software and services leadership positions at Juniper Networks, Oracle Corporation and Sun Microsystems. Phil Tinmouth, MBA Chief Business Officer Mammoth Biosciences Prior to joining Mammoth Biosciences in December 2022, Mr. Tinmouth served as Chief Business and Strategy Officer for Pardes Biosciences. From October 2002 through March 2020, Mr. Tinmouth served in various positions at Vertex Pharmaceuticals; most recently serving as Vice President and Head of Business Development & Alliance Management since July 2013. Between 1997 and 2002, Mr. Tinmouth occupied several roles at Bain & Company. His latest position was as a Senior Manager where he provided counsel on growth strategies to Fortune 50 pharmaceutical firms and smaller biotechnology companies. SPEAKERS
8 BACK TO QUICK LINKS EXHIBITORS www.marcumllp.com www.middlesexcountynj.gov www.princetonbiolabs.com www.ascendiapharma.com www.njeda.com/csit www.grantthornton.com www.asiwaste.com www.biobridges.com www.bomepharma.com www.eisneramper.com www.adp.com THANK YOU TO OUR PLANNING COMMITTEE Kathleen Addison, Executive Director, Life Sciences, J.P. Morgan Erin Beck, Business Development Manager, Morgan Lewis Claire Harnett, Associate Banker, Life Sciences, J.P. Morgan Aaisha Khan, Senior Marketing Manager, Morgan Lewis Steven Perdziola, Marketing Manager, Morgan Lewis Sabina Perchik, MS, Director, Transactions – Oncology Business Development, Johnson & Johnson David Schwartz, J.D., Partner, Morgan Lewis Adam Taliaferro, J.D., Director, State and Community Engagement, Johnson & Johnson www.fedsprout.com www.ascellahealth.com www.cfgi.com www.datasite.com www.dlapiper.com www.genvault.com www.jpmorgan.com www.njeda.com www.njhealthfoundation.org www.nj.gov/state/njic.shtml www.thermofisher.com www.withum.com
9 BACK TO QUICK LINKS Brian Lenz, CPA, MBA, Consultant & Board Director John Pennett, CPA, Partner-in-Charge, National Life Sciences & Technology Group, EisnerAmper Ravi Raghunathan, CPA, Partner, Life Sciences Industry Leader, CohnReznick Emilio Ragosa, JD, Partner, DLA Piper Sangeetha Ramsagar, Founder & CEO, Kronos Health Judith Sheft, MBA, Executive Director, New Jersey Commission on Science, Innovation and Technology Arda Ural, Ph.D., MSc, MBA, Partner, American Industry Market Leader, Health Science & Wellness, EY Jordan Warshafsky, MBA, EMTM, Partner, Ashton Tweed Joe Wolfe, Director, Business Development, RSM THANK YOU TO OUR COACHES Marshall Calman, MBA, PCC, Co-Founder & Principal, Leaderstrong Ahmet-Hamdi Cavusoglu , Ph.D., Program Director, Merck Digital Sciences Studio, NJIT Juliet Chin-Hart, MBA, CEO & Founder, Hart & Chin Brian Lenz, CPA, MBA, Consultant & Board Director Jack Levitt, MBA, EMTM, Co-Founder & Principal, Leaderstrong Scott Megaffin, CEO, Adiso Therapeutics, Board Member, BioNJ Ann Mohamadi, People Partner/Managing Director, Pharmaceuticals & Life Sciences, PwC Larry Samilow, Co-Founder & Managing Director, Verve Group Consulting Alain Van Loo, Founder, Assetive Jordan Warshafsky, MBA, Partner, Ashton Tweed Wayne Weiner, Ph.D., Principal, Pharma Tech Solutions Scott Alpizar, Ph.D., Principal, Emerging Innovations Consulting Jay Bhatti, Managing Director, 49 Alpha Glen Bressner, Co-founder & Managing Partner, Activate Venture Partners Gerry Brunk, Managing Director, Lumira Ventures Jarred Bressner, Ph.D., Principal, Activate Venture Partners Sheila Chandonnet, Member/Investor, Mid Atlantic Bio Angels, Partner, Life Science Legal John Coelho, Senior Advisor, Life Sciences Strategic Innovation Centers, New Jersey Economic Development Authority (NJEDA) Jim Gunton, Founder & Managing Partner, Tech Council Ventures Mark Kolb, Partner, Tech Council Ventures Demetrios Kydonieus, Founder Partner, Biotech Value Advisors Alan Lieber, Healthcare Executive Carolyn Myers, Principal, BioEnsemble Lorenzo Pellegrini, Ph.D., Managing Partner, Hatch BioFund Squire Servance, Ph.D., Founder & Managing Partner, Syridex Bio Yaniv Sneor, Founder, Mid Atlantic Bio Angels Sri Sriadibhatla, Investment Director, Ben Franklin Technology Partners Pannie Trifillis, Ph.D., Medical Affairs Executive Nishit Trivedi, Ph.D., Director, Life Sciences Research, Emerald Asset Management Mike Wiley, Vice President, Foundation Venture Capital Group Wesley Wilson, Managing Partner, Valorum Ventures THANK YOU TO OUR INVESTOR AND COMPANY OUTREACH COMMITTEE THANK YOU TO OUR PANEL OF JUDGES
10 BACK TO QUICK LINKS PRESENTING COMPANIES Company Room Time 4M Therapeutics Gamma Lab 1:20 p.m. - 2:30 p.m. 6S Pharma Interactive Theater 3:00 p.m. - 4:10 p.m. Abonics Interactive Theater 3:00 p.m. - 4:10 p.m. Accelerated Biosciences Gamma Lab 1:20 p.m. - 2:30 p.m. ACON Pharmaceuticals Gamma Lab 1:20 p.m. - 2:30 p.m. Addinex Technologies Interactive Theater 1:20 p.m. - 2:30 p.m. Adiso Therapeutics Gamma Lab 3:00 p.m. - 4:10 p.m. Advent Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. AGelity Biomechanics Gamma Lab 10:50 a.m. - 12:10 p.m. AOA Dx Delta Lab 1:20 p.m. - 2:30 p.m. ArrePath Delta Lab 10:50 a.m. - 12:10 p.m. Ascent Bio Delta Lab 10:50 a.m. - 12:10 p.m. Aspargo Labs Gamma Lab 10:50 a.m. - 12:10 p.m. Avistone Biotechnology Interactive Theater 10:50 a.m. - 12:10 p.m. Azome Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. Benevira Delta Lab 10:50 a.m. - 12:10 p.m. Biocentriq Delta Lab 3:00 p.m. - 4:10 p.m. BioLattice Ophthalmics Interactive Theater 1:20 p.m. - 2:30 p.m. Canget BioTekpharma Interactive Theater 10:50 a.m. - 12:10 p.m. Clinical Trials Interactive Theater 1:20 p.m. - 2:30 p.m. Couragene Delta Lab 10:50 a.m. - 12:10 p.m. Delphine Diagnostics Interactive Theater 1:20 p.m. - 2:30 p.m. DevaCell Gamma Lab 3:00 p.m. - 4:10 p.m. Dimer Health Interactive Theater 1:20 p.m. - 2:30 p.m. Enalare Therapeutics Gamma Lab 3:00 p.m. - 4:10 p.m. EpiBone Gamma Lab 10:50 a.m. - 12:10 p.m. FrontAim Biomedicines Delta Lab 10:50 a.m. - 12:10 p.m. Hanimune Therapeutics Gamma Lab 1:20 p.m. - 2:30 p.m. Hongyi Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. HopeAI, Inc. Interactive Theater 1:20 p.m. - 2:30 p.m. Iktos Delta Lab 3:00 p.m. - 4:10 p.m. Illuminare Biotechnologies Delta Lab 1:20 p.m. - 2:30 p.m. Inaedis Interactive Theater 1:20 p.m. - 2:30 p.m. Innerstill Interactive Theater 1:20 p.m. - 2:30 p.m. InteguRx Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. Intrommune Therapeutics Gamma Lab 1:20 p.m. - 2:30 p.m. Jubilant Therapeutics Interactive Theater 10:50 a.m. - 12:10 p.m. Kayothera Gamma Lab 3:00 p.m. - 4:10 p.m. Kognitic Interactive Theater 1:20 p.m. - 2:30 p.m. KolateAI PharmaTech Interactive Theater 1:20 p.m. - 2:30 p.m. Lactiga US Gamma Lab 3:00 p.m. - 4:10 p.m. LumaCell Interactive Theater 3:00 p.m. - 4:10 p.m.
11 BACK TO QUICK LINKS PRESENTING COMPANIES Company Room Time Mechano Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. Merlin Biotech Interactive Theater 10:50 a.m. - 12:10 p.m. Monarch Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. NanomediGene Delta Lab 1:20 p.m. - 2:30 p.m. NemaGen Discoveries Gamma Lab 1:20 p.m. - 2:30 p.m. NeuroPair Interactive Theater 1:20 p.m. - 2:30 p.m. Neuropathix Delta Lab 10:50 a.m. - 12:10 p.m. NuraLogix Gamma Lab 10:50 a.m. - 12:10 p.m. OLI Technologies Interactive Theater 1:20 p.m. - 2:30 p.m. Orbits Oncology Interactive Theater 3:00 p.m. - 4:10 p.m. Panavance Therapeutics Interactive Theater 10:50 a.m. - 12:10 p.m. Partex Delta Lab 3:00 p.m. - 4:10 p.m. PharmaNest Delta Lab 3:00 p.m. - 4:10 p.m. Pression Interactive Theater 1:20 p.m. - 2:30 p.m. Prima Innovations Interactive Theater 3:00 p.m. - 4:10 p.m. Regenosine Gamma Lab 3:00 p.m. - 4:10 p.m. Ricovr Healthcare Gamma Lab 10:50 a.m. - 12:10 p.m. Rx Bandz Gamma Lab 10:50 a.m. - 12:10 p.m. SciMar ONE Interactive Theater 3:00 p.m. - 4:10 p.m. Sen-Jam Pharmaceutical Gamma Lab 3:00 p.m. - 4:10 p.m. Sentauri Delta Lab 3:00 p.m. - 4:10 p.m. Sentrimed Interactive Theater 10:50 a.m. - 12:10 p.m. SFA Therapeutics Gamma Lab 1:20 p.m. - 2:30 p.m. Signum Biosciences Delta Lab 3:00 p.m. - 4:10 p.m. SkunkWorx Bio Delta Lab 10:50 a.m. - 12:10 p.m. Soligenix Interactive Theater 10:50 a.m. - 12:10 p.m. Somnia Therapeutics Delta Lab 3:00 p.m. - 4:10 p.m. Synergy Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. Taxis Pharmaceuticals Delta Lab 1:20 p.m. - 2:30 p.m. TelomEye Pharmaceuticals Gamma Lab 1:20 p.m. - 2:30 p.m. tenXclinical Interactive Theater 1:20 p.m. - 2:30 p.m. Thread Bioscience Gamma Lab 10:50 a.m. - 12:10 p.m. Torigen Delta Lab 1:20 p.m. - 2:30 p.m. TRIZ Biopharma Interactive Theater 1:20 p.m. - 2:30 p.m. Vasowatch Interactive Theater 1:20 p.m. - 2:30 p.m. Vaxine USA Delta Lab 1:20 p.m. - 2:30 p.m. Vital Start Health Delta Lab 3:00 p.m. - 4:10 p.m. VITRUVIAE Interactive Theater 3:00 p.m. - 4:10 p.m. Vuja De Sciences Delta Lab 10:50 a.m. - 12:10 p.m. Xiconic Pharmaceuticals Delta Lab 1:20 p.m. - 2:30 p.m. Zena Therapeutics Interactive Theater 3:00 p.m. - 4:10 p.m. Ziphius Delta Lab 10:50 a.m. - 12:10 p.m.
12 BACK TO QUICK LINKS 4M Therapeutics 4M Therapeutics develops new therapies for central nervous system disorders. Our living human brain cell platform was developed by our scientific founders at Harvard, MIT and the University of Washington. Lead compound 4MT2001 promises to be an effective, safer alternative to lithium and other medicines for bipolar disorder. A Phase 1 clinical trial is planned for 2025. The 4M pipeline is also relevant to other psychiatric disorders, Alzheimer’s disease and Parkinson’s disease. 4M is advancing new medicines that help brain cells make better connections. Contact: Pablo Lapuerta, Ph.D. Founder & CEO [email protected] Accelerated Biosciences We have a unique and proprietary stem cell platform, the human Trophoblast Stem Cell (TSC), and associated process technologies. We have a rich IP estate that completely protects our cell source and related applications. Our TSC platform is the best starting material for cell and gene therapy. Our TSC platform is the only ethically sourced pre-implantation stem cell platform that is GMP-grade, able to differentiate to all 3 germ layers, but a senescing stem cell platform that scales to 85x population doubling with stable karyotypes. Our TSCs, naturally, and simultaneously, perform functions of terminally differentiated cell types and are immune-privileged. Contact: Sicco Popma, Ph.D. Chief Scientific Officer [email protected] ACON Pharmaceuticals ACON Pharmaceuticals is a specialty pharmaceutical company and focuses on siRNA and mRNA nanoparticle delivery, long-acting microsphere product with its captive drug delivery and technology platforms. ACON is a privately held corporation located in Princeton, New Jersey. As a dynamic company in a vibrant life sciences research region, ACON leverages the expertise and experience of a highly skilled, multi-disciplinary workforce to accelerate drug development. We are currently raising a $5 million-dollar fund to support INDenabling studies for GalNAC siRNA for the treatment of hemophilia, lipid nanoparticle siRNA for the treatment of pulmonary fibrosis and long-acting microsphere for the treatment of schizophrenia. Contact: Xudong Yuan, Ph.D. CEO [email protected] Adiso Therapeutics Adiso Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of Patients and their families by creating novel and differentiated medicines to treat inflammatory diseases. ADS051 is an oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis, which has just completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year. Adiso is also developing ADS032, a novel small molecule, dual inflammasome inhibitor (NLRP1 & NLRP3) and is in advanced pre-clinical development in respiratory and dermal inflammation. Adiso is a member of the Morningside Ventures portfolio. Contact: Andrew Peranick Head of Strategy [email protected] EMERGING COMPANY PRESENTER PROFILES
13 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES AGelity Biomechanics Corp. AGelity Biomechanics is a private orthopedic device company seeking to commercialize its platform of non-degradable, off-the-shelf implants for the functional treatment of cartilage defects. AGelity’s initial focus is on cartilage lesions in the knee, a widespread problem for which there are no reliable early treatments. AGelity was co-founded by Dr. Russ Warren and Dr. Suzanne Maher and is the first spin-out from Hospital for Special Surgery. AGelity is a recipient of the prestigious NIH SBIR Phase I and Phase II grants and has received over $2 million in non-dilutive funding to date. Contact: Dennis O’Dowd CEO [email protected] AOA Dx AOA Dx is developing the next frontier in early stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring and eventually targeted therapies across multiple cancers. Contact: Oriana Papin-Zoghbi CEO [email protected] ArrePath ArrePath applies a proprietary multi-modal AI/ML approach to the discovery and development of new classes of antibacterials to address the global health crisis resulting from drug resistant infections. Our proprietary ML-enabled microscopy platform rapidly deciphers phenotypic outcomes to identify antibacterial compounds that engage with clinically novel biological targets. Predictive ML models are then applied to accelerate the drug discovery process through to development candidate. ArrePath is advancing its pipeline of new classes of antibacterials, focused on clinical indications associated with high unmet need, and further building its AI/ML platform to accelerate anti-infectives drug discovery. Contact: Alita Miller, Ph.D. Chief Scientific Officer [email protected] Ascent Bio Ascent Bio, a Yale University spinout co-founded by a team of AI researchers, is building an AI-first therapeutic design company focused on leveraging cutting-edge technologies to rapidly design small molecules with an emphasis on molecular glues in targeted protein degradation. Our core technology leverages powerful data-driven representations of molecules to more efficiently navigate and generate from large chemical spaces. The company was recently accepted into Merck Digital Science Studio. Contact: Kevin Bijan Givechian, Ph.D. Co-founder, President & Chief Scientific Officer [email protected]
14 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Aspargo Laboratories, Inc. Aspargo Laboratories is a leading commercial MedTech company based in Delaware. Our focus is on improving the quality of life and dosing adherence for users through our personalized drug delivery device. We achieve this by our suspension technology married to our patented drug delivery device. Our technology is applied to prescription (Rx) and over-the-counter (OTC) medications. Our first commercial product, Sildenafil Oral Suspension, is a revolutionary solution containing sildenafil citrate (the active ingredient in VIAGRA®), administered through a metered dose container. This innovative product has been approved for sale in Europe. Taking injectables and making them ingestible. Contact: Michael Demurjian Chairman [email protected] Avistone Biotechnology Avistone Biotechnology is a global oncology company, focused on targeted therapeutics for lung cancer. The company has six monotherapy assets in its portfolio/pipeline, including: • PLB1001 (Bozitinib): A Type 1b MET TKI conditional approved for MET Exon14 skipping (genetic) alterations NSCLC in China • PLB1004: An EGFR TKI for Patients with EGFR Exon 20 insertion mutations in NSCLC and in Patients with EGFR classical mutations • ANS01: A next-generation Type II MET inhibitor Avistone is exploring combination studies, including EGFR and MET and also has several other discovery/pre-clinical stage oncology assets currently under development. Contact: David Chung Chief Business Officer [email protected] Benevira Benevira’s prophylactic therapeutic products provide a radically different approach to developing broad spectrum antivirals. Using AI and Synthetic Biology, we have developed a new class of nanoparticle within our formulations that act as virus decoy particles. The nanoparticles display the receptor used by the virus to enter the host cells. Upon binding, the virus is either compelled to release its genetic material to an empty vessel or remain bound and inactive. The host cell receptors that Benevira’s formulation target are the evolutionary bottle neck for many viruses, thus creating broad spectrum capabilities (SARS-CoV1/2, RSV and Influenza A/B). Contact: Patricia Kitchen CEO [email protected] BioCentriq BioCentriq is a global cell therapy Contract Development and Manufacturing Organization (CDMO) with a proven track record successfully transferring, developing and manufacturing GMP drug product for use in clinical trials. This expertise, coupled with phaseappropriate quality systems and a modern infrastructure, have established BioCentriq as a trusted strategic partner for the development and manufacturing of autologous and allogeneic cell therapies. BioCentriq’s four flexible GMP manufacturing suites are supported by fully equipped process and analytical development laboratories to ensure seamless translation from the lab to the clinic. Contact: Alex Klarer Vice President, Business Strategy & Innovation [email protected]
15 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Canget BioTekpharma, LLC Canget BioTekpharma is a pharma company spun off in 2012 from Roswell Park Cancer Institute (RPCI, Buffalo, New York). Canget focuses on the discovery and development of novel small molecule cancer-targeting agents (exhibiting low toxicity to normal tissue, and high efficacy to cancer) that address multiple mechanisms of drug resistance. Initial indications are pancreatic cancer, colorectal cancer and prostate cancer. Contact: John Seman CEO [email protected] Couragene Couragene is a biotechnology company committed to building first-in-class in vivo genetic therapies using its proprietary delivery platforms. It is widely recognized that genetic medicines have the potential to transform the treatments of a variety of debilitating diseases. However, the fundamental challenge remains in finding a way to deliver genetic medicines to the targeted organs and cells in vivo. Couragene was founded to address this challenge head-on by developing a suite of first-in-class delivery platforms. Contact: Amy Liao, Ph.D. Co-founder [email protected] DevaCell DevaCell, a pioneering therapeutics company, leads in gene therapy with its innovative nanotechnology platform. DevaCell’s approach, proven effective in both in vivo and in vitro studies, achieves successful full-size gene replacement using a specialized hybrid viral vector. This method reduces immune responses, enabling lower doses, decreased toxicity and wider Patient reach. With a 10x higher genetic payload compared to AAV, repeat dosing is feasible. DevaCell’s nano-coating technology expands gene therapy applications, supporting multiple treatments, reducing doses and enhancing safety for a broader population. Currently seeking funding for preclinical POC for its active gene therapy program targeting Cystic Fibrosis. Contact: Inanc Ortac, Ph.D. Founder & Chief Scientific Officer [email protected] Enalare Therapeutics Enalare Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for Patients suffering from life-threatening critical care conditions and community-based health emergencies, including post-operative respiratory depression, community drug overdose and apnea of prematurity. Enalare’s lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. It utilizes the body’s own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in five human studies to date. Contact: Daniel Motto Chief Operating Officer [email protected]
16 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES EpiBone EpiBone is a pioneering regenerative medicine company at the forefront of bone and cartilage repair. Leveraging the power of stem cells, biomimicry and 3D fabrication, we are developing a pipeline of innovative products with enormous potential to revolutionize orthopedic repair. Our lead product, a living, anatomically precise 3D bone graft, completed its Phase I/IIa clinical trial in August 2023. The rest of our pipeline focuses on cartilage repair, and includes an allogeneic osteochondral plug, whose IND was approved in July 2023. EpiBone’s cartilage portfolio also includes an injectable cartilage filler that was partly funded by the Department of Defense. Contact: Sarindr Bhumiratana, Ph.D. Co-founder& Chief Scientific Officer [email protected] FrontAim Biomedicines FrontAim Biomedicines develops top-tier biomedicines targeting intractable cancers like triple-negative breast cancer, small cell lung cancer, hematological cancer and others. Our strategy is firmly rooted in cutting-edge technologies, including intracellular molecular grafting (MG) and MG-Ig bispecific 2.0 platform, alongside next-gen antibody-drug conjugates (NG-ADC). These innovations place us at the forefront of cancer drug development. With approximately $1.5 million funding from Sangel Capital and two PCT patents filed, we’re expanding our product pipeline, featuring T cell engager bispecifics and superior Trop2 ADCs for enhanced efficacy, safety and quality. Contact: Bill Liu, Ph.D. CEO [email protected] Hanimune Therapeutics Hanimune Therapeutics (HTx) is on the verge of filing an IND for its first oral allergy immunomodulation therapy. HTx will unlock the massive market of 35 million Americans with food allergies with its patented technology to reverse T-cell mediated disease, and a strategic approach to the Patients with the highest motivation to treat and the highest probability of success. HTx has clarified the path to BLA with the FDA, and the path to commercialization with strategic partners. HTx is raising a Series A for Phase 2 clinical studies, having de-risked clinical efficacy, regulatory requirements, market acceptance and the commercialization strategy. Contact: Meenal Lele Founder & CEO [email protected] Iktos Iktos develops innovative AI Artificial Intelligence technologies based on deep learning generative algorithms to accelerate drug discovery projects. Deep Generative Chemistry modeling for de novo design to expedite structure and ligand-based hit discovery, hit expansion and lead optimization projects. Data driven Retrosynthesis Analysis to explore potential synthetic routes of a given compound and for high-throughput assessment of synthetic accessibility. DockAI: Ultra-large virtual screening powered by active learning – high quality virtual screens. Significant accuracy and efficiency improvements in a benchmark versus industry peers. The high throughput virtual screen (several billion compounds) can be accomplished within 24-72 hours Contact: Philip Laut Vice President, Head, US Sales, BD & Operations [email protected]
17 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Illuminare Biotechnologies Illuminare Biotechnologies is a clinical-stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage. Our proprietary lead candidate, Illuminare-1, is a small molecule with an immediate onset of action and sustained duration of nerve illumination. The IND for Illuminare-1 is currently conducting a first-in-human Phase 1 clinical trial in radical prostatectomy at Memorial Sloan Kettering Cancer Center to demonstrate safety and initial efficacy improving visualization of nerves. The company expects to enter Phase 2 in 2024 in open hernia repair and other open and minimally invasive surgical indications. Contact: Walter Greenblatt CEO [email protected] Intrommune Therapeutics Intrommune Therapeutics is a clinical-stage biotechnology company developing Patient-friendly therapies for the treatment of peanut and other food allergies. The company’s initial product, INT301, is an allergy immunotherapy treatment delivered via a specially-formulated toothpaste designed to optimize exposure of allergenic proteins to a Patient’s immune system while also cleaning their teeth. This approach, known as oral mucosal immunotherapy (OMIT), drives the immune system toward specific tolerance. As part of a Patient’s daily routine, OMIT toothpaste is regularly exposed to oral tissues and then expectorated, avoiding the significant adverse events caused from ingesting allergenic food proteins. Contact: Stuart Loesch President [email protected] Jubilant Therapeutics Jubilant Therapeutics is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined Patients. The company’s pipeline consists of a first-in-class dual coREST modifier, JBI-802, currently in a Phase I/II clinical trial in multiple tumors, a novel brain-penetrant modulator of PRMT5 for which an IND has been accepted, brain penetrant PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications. The company is headquartered in Bedminster, New Jersey and guided by globally renowned scientific advisors. Contact: Shyam Pattabiraman Chief Financial Officer [email protected] Kayothera Kayothera has developed a pipeline of first-in-class, exceptionally safe, oral retinoid pathway antagonists that offer a unique platform to treat various cardiometabolic diseases and cancer. Therapies in Kayothera’s pipeline inhibit distinct enzymes in the retinoid pathway that drive disease progression in type 2 diabetes and obesity, while other pipeline therapies reverse immune suppression in multiple genetically defined and high-need cancer types. The lead program, KAYO-1609, is currently in IND-enabling studies to support a Phase 1 trial in early 2025 in healthy Patients, while additional programs are slated for clinical entry in 2026. Contact: Mark Esposito, Ph.D. Founder & CEO [email protected]
18 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Lactiga US Lactiga is an award-winning, visionary biotechnology company committed to pushing the boundaries of medical science and improving the lives of immunodeficient Patients through innovative mucosal therapies. Contact: Rikin Mehta, Pharm.D., J.P. Co-founder [email protected] Merlin Biotech Merlin Biotech is a pre-clinical stage mRNA platform company with a novel first-in-class cancer immunotherapy with exclusive IP in major worldwide markets. Our target, USP6, has demonstrated in vivo efficacy with supporting human epidemiological survival data. These data support a broad cancer indication with an adult market estimated 5-year sales at $2 billion. Contact: Randall Hyer, Ph.D. CEO [email protected] NanomediGene NanomediGene is a biotech company specializing in developing nanotechnology and drug delivery systems to enhance the quality of life for Patients with chronic and genetic diseases. Our primary focus is on targeted gene delivery systems. We have developed groundbreaking technology called the NanoGene film, a local and targeted drug delivery platform that addresses the challenges faced by individuals with breast cancer. Utilizing nanoscale materials and techniques, we aim to enhance pharmaceutical agents’ targeted delivery, efficacy and safety. Contact: Yasin Oduk, Ph.D. Founder & CEO [email protected] NemaGen Discoveries NemaGen Discoveries is a New Jersey-based, preclinical biotechnology company developing first-in-class therapeutics for Patients suffering from severe allergic disorders and pulmonary fibrosis. Contact: Nick Shubin, Ph.D. CEO [email protected]
19 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Neuropathix Neuropathix is a drug discovery company with globally patented anti-inflammatory technology. Our lead compound KLS-13019, is a first-in-class, non-opioid, non-NSAID that has been validated through IND enabling studies to prevent and reverse chemotherapy induced peripheral neuropathy (CIPN). Preclinical animal studies to date indicate KLS-13019’s ground-breaking potential in treating neuro-inflammation, neuropathic pain, and opioid use disorder. In addition to our drug’s ability to reverse neuropathic pain, animal studies have shown KLS-13019’s ability to reduce morphine reward seeking (addiction), and withdrawal symptoms (aggression and anxiety) caused by the use of naloxone after chronic morphine dosing. Contact: Dean Petkanas CEO [email protected] NuraLogix NuraLogix is a pioneer in the development of Affective Ai™ and the creator of the world’s first contactless blood pressure measurement technology. The company’s patented cloud-based Affective Ai™ Platform- DeepAffex™ can measure over 100 health and wellness parameters using a conventional video camera and its patented Transdermal Optical Imaging (TOI™) technique to extract facial blood flow information from the human face. This is demonstrated in the company’s groundbreaking Anura™ app. Contact: Vince Traylor Director, Sales & Partnerships, U.S. Market [email protected] Panavance Therapeutics Panavance Therapeutics is a privately held clinical-stage oncology company developing misetionamide (GP-2250), a novel MOA tumor cell selective agent. Misetionamide is a broadly antineoplastic small molecule with a unique MOA which: 1) Selectively disrupts the energy metabolism of cancer cells leading to cancer cell death; and 2) directly impacts nuclear factor-κB (“NFκB”) which affects the cancer cells’ ability for protein and DNA transcription thereby restricting cancer cell growth and proliferation. As we complete an on-going Phase 1 clinical trial, we are seeking financing and partnering opportunities for a Phase 1b-2 study for the treatment of platinum resistant ovarian cancer. Contact: Greg Bosch Chairman & CEO [email protected] Partex Partex is solving the inefficiency problem of the life sciences industry in drug discovery and development using Big Data & Artificial Intelligence. Our business units cover a full range of services: Incubation (AI-driven in-licensing of undervalued assets and cash-efficient development until inflection points), Validation (Experimental real world validation of AI-generated hypotheses), Insights (Enabling life sciences partners to position drug assets optimally and accelerate drug discovery and development), Technology (Tech software and infrastructure, including computing capabilities (NVIDIA GPUs)), Data (Licensing data or custodian services for public and proprietary data) and Financial Asset Management of incubated drug assets. Contact: Gunjan Bhardwaj, Ph.D. Founder & CEO [email protected]
20 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES PharmaNest PharmaNest is a Princeton-based Digital Lab specialized in the development and validation of new Digital Pathology AI biomarkers for the quantification of Fibrosis and Inflammation. Contact: Mathieu Petitjean, Ph.D. CEO [email protected] Regenosine Regenosine, based in Princeton, NJ, is a privately held company developing a first-in-class disease modifying regenerative therapy for osteoarthritis (OA). Our proprietary product harnesses the healing potential of the purinergic system – critical in maintaining cartilage homeostasis. Our product targets a rapidly growing joint preservation market. We have demonstrated that our therapy can prevent the progression of OA, significantly reduce joint pain and restore joint function – a competitively unique offering. Regenosine is led by a stellar word-class team, and has 11 worldwide patents. We anticipate beginning our Phase-1b/2a POC clinical trial in patients with knee OA in late 2024. Contact: Sid Angle, Ph.D. Co-founder & CEO [email protected] Ricovr Healthcare Ricovr is revolutionizing diagnostics with a point-of-care saliva-based rapid detection platform. Our first offering, a highly precise and affordable cannabis testing device, serves employers, law enforcement and government sectors. Lacking the need for FDA approval in the business and insurance sectors, we have the unique advantage of rapidly introducing our product to a vast market. Published in top scientific journals, our technology promises expansion into vital areas like reproductive health, infectious diseases and cancer diagnostics. We’re currently developing an accurate test for Preeclampsia, a life-threatening pregnancy complication – a project that garnered us an award from the NJEDA. Contact: Piyush Sadana Co-Founder & Chief Operating Officer [email protected] Rx Bandz Rx Bandz has developed the next generation of Patient-centric auto-injectors and life-saving formulations for Patients around the world. Designed to treat numerous emergency medical conditions, its MiniJect is the world’s smallest auto-injector that is safer, faster, rugged and easier to use than traditional auto-injectors. Our drug delivery platform and internal technology can be easily adapted to extend the shelf life of many drugs and deliver highly viscous biologics and vaccines <1 ml to 5 ml via IM or SubQ. Contact: Jessica Walsh Founder & CEO [email protected]
21 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Sen-Jam Pharmaceutical Sen-Jam is developing a platform of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion-dollar market that has seen little innovation in the past 30 years. We are developing assets to uniquely reduce pain and inflammation by harnessing your body’s immune system, at the very beginning of the inflammatory cascade. We seek to prevent acute inflammation, slow the progression of inflammatory chronic illnesses, and improve health span. We offer to the consumer in the OTC and Rx strength, products that can be used safely and preventatively, to reduce inflammation by greater than 30%. Contact: Jacqueline Iversen, RPh, MS Co-Founder & Chief Clinical Officer [email protected] Sentauri Careful investigation of the Protein Data Bank reveals that a large number of ligand bound structures are poorly fit to the experimental electron density. Moreover, the modeled ligands are in high energy conformations, incongruent with expectations from QM. Because the fidelity of these data form the basis of structure based drug design, the consequences of ill-fitting structure are enormous, leading to massive difficulties in tractability and SAR. Sentauri has developed a novel physics-based reinforcement learning program which fits ligands to electron density more accurately and quickly than modern tools. Contact: Sam Giannakoulias Founder & Chief Technology Officer [email protected] Sentrimed Sentrimed is creating safer, oral oncology therapies that harness cell-to-cell communication pathways critical to reviving the body’s ability to recognize, immobilize and eliminate tumor cells. Our lead product, MASL®, is an orally dosed lectin and a potent inhibitor of podoplanin that impacts multiple oncogenic signaling pathways. Animal studies showed a 10-fold inhibition of tumor growth without identifiable adverse effects or histological changes. MASL demonstrated both cytostatic effects (cell motility inhibition of 86%) and cytotoxic effects (cell viability inhibition of 75%) on human oral squamous cell carcinoma. MASL is currently being studied in an NIH funded oral cancer human signal trial. Contact: Bill Ragatz President & CEO [email protected] SFA Therapeutics SFA Therapeutics is a clinical-stage biotech developing first-in-class oral drugs that block autoimmunity by upregulating IL-10 and downregulate a cascade of inflammatory cytokines, including TNFa, IL-23, IL-17 and IFNg. In a Phase 1b clinical trial in psoriasis, as a proof of concept for SFA-002 showed: • 92% of Patients showed PASI>50 improvement • 72% of Patients showed PASI>75 improvement • 70% is mean PASI improvement in all subjects • 87% is mean PASI improvement in subjects with PASI>75. The therapeutic index is very high; and no related AEs were observed • SFA holds over 15 patents in 40 autoimmune diseases, including Composition of Matter Contact: James Kirwin Chief Operating Officer & Head, Development & Operations [email protected]
22 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Signum Biosciences Signum Biosciences is a biotech spun out of Jeffry Stock’s lab at Princeton University in 2002 established as a C Corp. in Monmouth Junction. Epicutis Skincare: Signum’s new professional channel global brand launched August 2021 with over $7M in sales through December 2023 Partnerships with HydraFacial: Global launch of Epicutis booster Partnerships with Equinox: Luxury Fitness/Spa Epicutis launched Globally in the US, Japan, UAE, UK, France, Canada, Mexico, Hong Kong, and the Caribbean Patent protection via issued, pending and provisional patents covering composition-of-matter, methods-of-use. Contact: Maxwell Stock Co-Founder, President & CEO [email protected] SkunkWorx BioPeptide Drug conjugates (PDCs) have garnered attention for their ability to deliver tumor-specific drugs while significantly reducing systemic toxicities. PDCs are attractive therapeutics which overcome the efficacy and toxicity hurdles of traditional chemotherapy and ADCs. Skunkworx Bio has developed a series of technology platforms for the generation of both novel PDCs and single domain drug conjugates targeting important tumor-associated antigens. The company has several leads which have shown efficacy both in vitro and in animal models. Skunkworx is looking for partners interested in its platform or to work with it to move its leads into clinical development. Contact: Neil Goldstein, Ph.D. Chief Scientific Officer [email protected] Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, Behçet’s disease and pediatric Crohn’s disease; and 2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure and viral disease including Ebola, Marburg and COVID-19. Contact: Jonathan Guarino Senior Vice President & Chief Financial Officer [email protected] Somnia Therapeutics Somnia Therapeutics is a biopharmaceutical start-up developing an oral treatment for obstructive sleep apnea (OSA), one of the largest unmet medical needs affecting 54 M Americans. Somnia’s drug candidate (SMT-001) has been studied and shown the promising clinical efficacy in preliminary proof-of-concept clinical studies with OSA Patients. The drug has an established excellent safety profile for chronic use in humans. The U.S. market for Somnia is estimated to be multiple-billion dollars. Somnia’s founders are serial and productive entrepreneurs, and previously co-founded Amicus Therapeutics. Somnia is raising funds for the formulation development and its clinical trials. Contact: Jim Fan Co-Founder & CEO [email protected]
23 BACK TO QUICK LINKS EMERGING COMPANY PRESENTER PROFILES Synthis Therapeutics Synthis Therapeutics is a biotech company developing the next generation of targeted TGFb therapies for cancer Patients. Our lead drug, SYN101, is a first-in-class, targeted TGFb inhibitor that selectively and safely blocks immune suppression to drive tumor clearance. Compared to systemic TGFb inhibitors that cause cardiac toxicity, SYN101 is safe. Synthis is the only company developing an immunomodulatory ADC conjugated to a TGFb inhibitor. We have multiple issued patents and are raising a $30M Series A for first in human studies. SYN101 overcomes the limitations of systemic TGFb therapeutic approaches to improve the therapeutic window and efficacy. Contact: Dori Thomas-Karyat, Ph.D. CEO [email protected] Taxis Pharmaceuticals Taxis Pharmaceuticals is a clinical-stage company developing anti-resistance drug candidates against ESKAPE pathogens. Our pipeline includes several investigational agents with novel mechanisms of action, including efflux pump inhibition (EPI) and bacterial protein FtsZ modulators (currently in Phase I). Resuscitating the activity of generic antibiotics would facilitate access to inexpensive, life-saving medications across the globe. In 2020, CARB-X awarded TAXIS $3.2 million and in February 2024, NIH awarded Taxis ~ $3M, to develop EPIs. Our portfolio also includes novel dihydrofolate reductase inhibitors that have significant potency against Neisseria gonorrhoeae, a.k.a. “Super Gonorrhea’ – a deadly strain that is nearly untreatable. Contact: Gregory Mario CEO [email protected] TelomEye Pharmaceuticals At TelomEye Corporation, our mission is to transform lives by using 2009 Nobel Prize winning technology Telomere Science within cellular tissues of the eye. Our flagship program is dedicated to Fuchs endothelial dystrophy, a progressive corneal disorder that affects vision after the age of 40, leading to blindness. Currently, the sole treatment option is corneal transplantation. TelomEye is pioneering a novel approach by harnessing telomerase activation therapies aim to prevent damage to endothelial cells and enhance corneal health. TelomEye’s research and development promises a brighter future for those battling presbyopia, age-related macular degeneration and cataracts all within our company pipeline. Contact: Kubi Turkmen Co-Founder & CEO [email protected] Thread Bioscience Healthcare workers are in need of accurate data to provide proper diagnosis and monitor Patient vitality. Thread Bioscience applies technology to in-situ bacterial testing using a culture technique. Thread’s CultureStat rapid test for Urinary Tract Infection (UTI) distinguishes between lag and log phase bacterial growth with a diagnostic test that is both accurate and fast. Thread’s SentiLiter Patient fluid monitoring and measuring platform uses non-contact sensors and a sophisticated mobile app to provide real time insight into patient fluid dynamics. SentiLiter allows a healthcare provider to remotely monitor Patient fluids and establish parameters for notifications in the mobile app. Contact: Craig Serio Founder & CEO [email protected]
24 BACK TO QUICK LINKS Torigen Torigen focuses on providing veterinary immunotherapies for companion animals with cancer and autoimmune diseases. Torigen’s first commercial product is an autologous cancer immunotherapy that uses the Patient’s own tumor cells to create a personalized treatment to fight the cancer. With over 50% of companion animals over the age of 10 dying from cancer and with other treatment modalities being both expensive and having negative side effects, Torigen’s Autologous Prescription Product, VetiVax, is an innovative new treatment that is quickly gaining traction with veterinarians across the country. Torigen addresses a multi-billion-dollar market opportunity within animal health. Contact: Ashley Kalinauskas CEO [email protected] Vaxine USA Vaxine USA, a start-up biotechnology company, applies immune signaling pathways knowledge to develop precision immunotherapy against cancer. Vaxine tackles cancer immunotherapy from different complementary approaches. Radvax, a personalized autologous cancer vaccine combined with Advax has entered Phase 1 studies, with encouraging results. Additionally, Vaxine has an AI-assisted platform to discover innate immune activators to enhance tumor immunogenicity. Vaxine uses cancer cell DNA deep sequencing to identify key driver mutations that may be targeted by adjunct therapy or to develop epitope-based synthetic T-cell vaccine antigens. These cancer vaccine approaches can be combined with checkpoint inhibitors, chemotherapy or radiotherapy for optimal activity. Contact: Diego Silva, Ph.D. Managing Director USA - CMO [email protected] Vital Start Health Vital Start Health is a UPenn start-up with the first VR assisted reproductive and maternity mental health platform. Founder & CEO, Kirthika Parmeswaran, is a Wharton alum with deep expertise across business and technology. Co-Founder, John Chuo, M.D. is the Chief Scientific Advisor, Professor at Penn Medicine, and Neonatal Quality Officer at the Children’s Hospital of Philadelphia. We have won numerous awards, launched platform, filed IP, completed feasibility studies, secured licensing with the Children’s Hospital of Philadelphia and are currently in the Azure Marketplace working with Health Systems and Employer customers. With $500k in funding, we are currently raising seed. Contact: Kirthika Parmeswaran Founder & CEO [email protected] Xiconic Pharmaceuticals Xiconic is a privately held biopharma company developing its novel XCN-010 antibody-drug conjugate (ADC) based on intellectual property from Rutgers University. The central component of XCN-010, the monoclonal antibody, targets a unique tumor-associated antigen, activated matriptase (actM), which is highly expressed by a variety of epithelial-derived tumors but negligibly expressed by normal healthy tissue. Preclinical data indicate potentially broad applications as a single product to treat multiple tumor types, including breast cancer, non-small cell lung cancer, prostate cancer and gastric cancer, as well as B-cell cancers such as mantle-cell lymphoma. The company is seeking funding to conduct key IND-enabling activities. Contact: Brian Pusch Secretary, Treasurer & Director [email protected] EMERGING COMPANY PRESENTER PROFILES
25 BACK TO QUICK LINKS Ziphius Ziphius is a biotechnology company focused on the development of self-amplifying RNA-based (saRNA) vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform to allow for a higher and prolonged protein/antigen expression at lower doses (compared to conventional mRNA) with reduced toxicity. This platform has the potential for a ‘plug and play’ approach offering the possibility of fast development/scale-up and production. These attributes make it a well-suited platform to improve pandemic preparedness. Our present pipeline showcases strategic developments in infectious diseases, protein replacement therapy and a cutting-edge oncology program. Contact: Hanne Noyen Scientific Liaison Manager [email protected] EMERGING COMPANY PRESENTER PROFILES START-UP PRESENTATION PROFILES 6S Pharma 6S Pharma pioneers healthcare innovation, addressing unmet needs by repurposing approved drugs for new indications – shaping a dynamic portfolio with strategic expansion into complex generics. The 505(b)(2) product lineup, targeting diverse indications with a market size exceeding $2 billion, integrates seamlessly with global marketing strategies. The successful out-licensing of a complex generic formulation underscores our strategic collaborations. Currently, we’re preparing IND applications and conducting bioequivalence studies for our complex generics. We invite partners and investors to join us on this exciting journey, supporting the development of our distinctive portfolio. Contact: Ashok C. Illapakurthy, Ph.D. Founder & CEO [email protected] Abonics Abonics is a medical device company dedicated to delivering standalone, fast and accurate diagnostic tools for global health improvement. Abonics is currently developing a multiplex assay functioning point-of-care diagnostic device using finger-stick blood samples that can provide Patients with instantaneous, fast and accurate quantitative detection results for ovarian cancer screening and monitoring. Contact: Eon Soo Lee, Ph.D. Founder [email protected]
26 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES Addinex Technologies Addinex offers a low-cost prescription drug dispensing system to reduce medication misuse and addiction. Our patented dispenser limits access based on a Patient’s prescription (e.g., 1 pill every 4 hours) while educating Patients on proper use and risks. Our mobile app collects Patient data and progress to allow a clinician to avoid overprescribing and remotely manage a Patient’s treatment. When done, the Patient simply returns any leftover pills in a DEA-approved mailer for safe disposal. Contact: Jay Schiff Co-Founder & CEO [email protected] Advent Therapeutics Advent was formed by a senior industry executive with neonatal, pediatric and orphan drug expertise to address serious unmet medical needs. Advent has developed a novel, late-stage, metabolic and reparative therapy, optimized to address neonatal Bronchopulmonary Dysplasia (BPD), the most frequent serious complication of prematurity. BPD results in significant morbidity and mortality and has no approved therapies. Advent has been awarded $5.6M in NIH funding, has received both U.S. and EU Orphan Drug Designations and was granted FDA Rare Pediatric Disease Designation for BPD. Our lead product is approvable within 16 months for $1.5M manufacturing with no additional clinical trials anticipated. Contact: David L. Lopez Co-Founder & CEO [email protected] Azome Therapeutics Azome Therapeutics was founded by University of Florida’s Chair of Pediatrics, Dr. Rashmin Savani and former Mallinckrodt Pharmaceuticals executives with a mission to revolutionize the treatment of inflammatory diseases. We are focused on severe acute inflammatory diseases and injuries that share a common biological mechanism: the NLRP3 Inflammasome. These inflammasome-mediated diseases include bronchopulmonary dysplasia (BPD), acute respiratory distress syndrome (ARDS), exacerbations in idiopathic lung fibrosis (ILF), acute lung injury, acute kidney injury and sepsis. By specifically targeting the earliest activation signal for inflammasome activation, Azome’s technology represents a platform approach for addressing these severe unmet clinical needs. Contact: Elliott Gruskin, Ph.D. CEO [email protected] BioLattice Ophthalmics We are addressing the need for tissue repair solutions, beginning with cornea. Globally only 1 in 70 Patients who need cornea tissue receive it and two million per year suffer from corneal blindness while only 200,000 per year receive vision restoration via cornea transplant, 13 million globally are on a donor cornea waiting list. There is currently no standard of care alternative to donor cornea tissue for full thickness cornea transplant (penetrating keratoplasty). We are currently creating an ambient temperature stable engineered cornea (CorneaClearTM) that is intended to be a standard-of-care material for full thickness cornea replacement. Contact: Amelia Zellander, Ph.D. CEO [email protected]
27 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES Clinical Trials, LLC Clinical Trials was created to transform clinical trial recruitment for pharmaceutical companies, CROs and trial sites by expediting trial recruitment and providing higher qualified leads to clinical trial stakeholders. Clinical Trials is developing clinicaltrials.co to bridge the gap between pharmaceutical companies/CROs conducting clinical trials and Patients utilizing a proprietary technology platform that offers a suite of information and services. These tools include information about the clinical trial process, news about relevant clinical trials, tools enabling a direct connection between Patients and pharmaceutical companies/CROs, as well as comprehensive proprietary and easy to understand listings of trials. Contact: Rivka Szafranski Co-Founder & CEO [email protected] Delphine Diagnostics Delphine Diagnostics is innovating on two products: a molecular diagnostics assay (device), and an artificial intelligence-based (AI ML) Clinician Assistant tool. Both products are in the sepsis medical diagnostics space and will enable better and much faster diagnosis of sepsis. The problem is too big to ignore. As per CDC data, we have been losing around 270,000 precious lives in the United States every year to Sepsis. Delphine Diagnostics aims to drive significant improvements to current Standard of Care (speed and accuracy), saving more lives and increasing the quality of life for survivors. Contact: Andy Bala Founder & CEO [email protected] Dimer Health Our mission is to provide personalized and technology-driven healthcare solutions to support Patients post discharge, so they can stay healthy and independent. Dimer Health enables successful transitions through our AI-powered clinical service platform. Our differentiating software enables us to connect with the Patient while they are still in the facility and extends into the home. We optimize Patient transitions. Contact: Gidon Coussin Chief Business Officer [email protected] Hongyi Therapeutics Hongyi Therapeutics is a biotech start-up focused on developing target therapeutics for the treatment of brain cancers and other CNS disorders. Our developed small molecular compounds showed significant efficacy against Glioblastoma in animal studies and potential for Alzheimer’s disease. These compounds also exhibit desirable PK and toxicity profiles. GBM remains one of the most difficult-to-treat cancer types, and there is an immense unmet medical need to develop more effective targeted therapies for this fatal disease. We are dedicated to bringing our product to clinical stage for the Patients who desperately need new medications. Contact: Weilin Sun, Ph.D. Founder [email protected]
28 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES HopeAI At HopeAI, we are on a mission to bring hope to Patients by accelerating the clinical development of new treatments through AI. Patients can’t wait. We believe AI-enabled clinical trials are the key to bringing life-saving drugs to Patients faster and more efficiently. Our initial approach involves crafting an AI co-pilot with up-to-date clinical evidence and profound statistical insights. This AI co-pilot will work alongside the clinical development team to make swift and data-optimized decisions throughout trial design and execution, enhancing probability of success and expediting time to market. Contact: Will Ma, Ph.D. CEO [email protected] Inaedis Inaedis is a spin-out company from Princeton University developing a pharmaceutical platform changing the future of drug development, delivery and distribution by powderizing liquid biologics and vaccines. First developed by Princeton scientists during the COVID-19 pandemic, their goal was to give everyone access to the miracles of modern medicine. Inaedis invented proprietary Rapid Room-Temperature Dehydration platform technology, which solves the global dilemma posed by the thermal stabilization requirements of life-saving heat and freeze-sensitive vaccines and biologics. Contact: Maksim Mezhericher, Ph.D. Founder & CEO [email protected] Innerstill Innerstill is a neurotech company launching bioelectrical stimulation solutions that balance neuro-hormones essential for healthy living. In Q4 2023, the company launched the consumer wellness product ‘mindvybe’, a patented vagus nerve and acupoint stimulator that helps to alleviate symptoms of stress, improving focus, cognition and overall wellness. In late 2024, Innerstill will submit a 510K application to FDA for addiction recovery using a clinical model of mindvybe. This year, the company will also request FDA pre-sub meetings for their non-invasive deep brain stimulator using interference current for the attenuation of early dementia. Contact: Ellyn Ito Co-Founder & CEO [email protected] InteguRx Therapeutics InteguRx Therapeutics is dedicated to applying innovative transdermal drug delivery technologies to address Patients’ needs not satisfied by current therapies. We have developed a proprietary skin penetration enhancement system which achieves extraordinary increases in drug permeation through human skin. Currently we are developing transdermal patches which deliver the antinauseant ondansetron and the anticoagulant apixaban – the former to avoid oral administration in pregnancy-induced nausea and vomiting for women with severe symptoms, and the latter to treat atrial fibrillation while eliminating the twice-daily concentration peaks of oral dosing, in hopes of reducing hemorrhagic adverse events associated with apixaban therapy. Contact: Gary A. Shangold, MD Founder & CEO [email protected]
29 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES Kognitic Kognitic is a data analytics platform designed for the life sciences industry, providing real-time insights into clinical trials and drug development. It offers a comprehensive view of the competitive landscape, helping pharmaceutical and biotech companies make informed decisions. Kognitic’s platform integrates data from various sources, including trial registries, publications and regulatory filings, to deliver actionable intelligence on drug pipelines, trial designs and market trends. By leveraging advanced analytics and visualization tools, Kognitic empowers stakeholders to stay ahead in the rapidly evolving healthcare sector and accelerate the delivery of innovative therapies to Patients. Contact: Aquil Ahsan Founder & CEO [email protected] KolateAI PharmaTech KolateAI drives accelerated and targeted pharma clinical trials with our trial events prediction engine and co-pilot that enable in-trial course correction. Our goal is to mitigate the 90% clinical development failure rate and $1-2B cost per drug. We can assist in stopping non-working trials early or in streamlining working trials. With our predictions of AE’s, drug response and trial end points, working in concert with our Gen AI Co-pilot, we can: 1) identify best-performing patient cohorts in advance, 2) provide advance view of trial direction by comparison of treatment vs. control trial arms and 3) enable effective real-time trial management. Contact: Vinodh Balaraman Co-Founder & CEO [email protected] LumaCell Lumacell designs and develops whole cell biosensors for the detection of G-protein Coupled Receptor (GPCR) ligands in diagnostic applications. The company’s platform technology affords customers the specificity of functional analysis without sacrificing the flexibility and economic advantages of immunoassays. Lumacell will initially service the performing laboratory market within the drug screening, pain management and metabolic health verticals while continuing to develop portable solutions that leverage its platform’s capability. Contact: Daniel Cohen Co-Founder & CEO [email protected] Mechano Therapeutics Spun out of the University of Pennsylvania, Mechano Therapeutics is a biotech specializing in microcapsule development using proprietary microfluidics for drug encapsulation and optimizing drug performance. Contact: Nick DePhillipo Ph.D. Co-Founder & Chief Operating Officer [email protected]
30 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES Monarch Therapeutics Monarch Therapeutics is a pre-clinical, seed-stage company developing innovative cell therapies for solid tumors and autoimmune indications. Monarch Therapeutics has differentiated platform technology that is spinning out of the University of Pittsburgh enabling the development of universal, tunable and scalable cell therapies that can target multiple disease associated antigens and overcome biological challenges that are present in many solid tumors and autoimmune indications. Contact: Christopher Potts CEO [email protected] Neoventech Neoventech is a specialty pharmaceutical company focused on developing new topical and transdermal drug delivery technologies and products. We are committed to providing effective treatments for difficult-to-treat chronic dermatological conditions via novel drug delivery technologies. We also provide topical product development R&D service to the pharmaceutical industry with integrated formulation development, product characterization. Contact: Jeffrey Wu CEO [email protected] NeuroPair NeuroPair is an early stage medical device company developing products to regenerate and re-connect neurons after spinal cord injury. An injectable gel formulation uses magnetically aligning nanoparticles to create a fiber scaffold in the injury site that supports and guides neuronal regrowth. Axons are like wires that connect neurons in the brain and spine. If axons are damaged in an injury, the communication is lost, resulting in loss of control (motion, bladder, bowel, sexual) and sensation (feeling, pain, position). Damage to the spinal cord has devastating and irreversible consequences. Costs after injury exceed $2M per Patient. Contact: Johannes Dapprich, Ph.D. Founder & CEO [email protected] OLI Technologies OLI is building the world’s first portable dialysis device, small enough to fit in a backpack, enabling convenient kidney care from virtually anywhere. Our breakthrough is perfectly timed to disrupt the $50B U.S. dialysis market, as recent regulatory initiatives have greatly incentivized treatment centers to start promoting remote care. OLI’s device implements a novel recycling process to shrink the wasteful amount of highpurity water needed for treatment 200-fold, dramatically reducing the footprint and cost of care. Contact: Tom Weindl CEO [email protected]
31 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES Orbits Oncology Orbits Oncology uses a platform-as-a-service model and offers tiered access to our digital platform: 1) basic organoid analysis or 2) advanced analysis based on our digital twins. Our basic tier provides drug metrics that outperform the industry standard, and our premium tier enables clinical prediction and biomarker discovery. Initial pricing is set to $100k/yr (basic) and $500k/yr (premium), based on comparable analysis offerings and value of clinical insights for drug development, respectively. Contact: Abraham Lin, Ph.D. CEO [email protected] Pression Seventeen million Americans suffer from coronary artery disease and two million of those will develop refractory angina. Standard of care delivers subpar outcomes. A large body of data suggests a non-invasive treatment, External Counterpulsation, provides relief for >80% of Patients. Cost, convenience and access have limited adoption. Pression’s Wave PRO overcomes these limitations and may offer an effective option to Patients who remain untreated and in pain. Wave is automated, comfortable and cost effective for Patients, providers and payers. National coverage exists with both Medicare and private insurance, with $7B TAM. Pression had its presubmission meeting and is ready for clinical trial. Contact: Adam Salamon, Ph.D. Founder & CEO [email protected] Prima Innovations Muscle pain and spasm are the most common problem impacting the quality of life affecting nearly 2 billion people world-wide. To date, there is no FDA approved Topical Muscle Relaxant (MR). Currently available products like Diclofenac and Lidocaine work through anti-inflammatory or anesthetic mechanisms, respectively. They only treat symptoms and do not work on muscle spasms directly. Prima Innovations has developed a novel muscle relaxant in cream that works in minutes without side effects like drowsiness or headache experienced by other oral MR. Proof of the principle has been established through many animal models, some of which will be discussed. Contact: Mandar Shah, Ph.D. Chief Scientific Officer [email protected] SciMar ONE SciMar will reduce pharmaceutical R&D costs and increase ROI by identifying and removing inefficiencies in strategic drug development using our products for Development Velocity™ (DV™). Removing inefficiencies will accelerate new therapies to market for longer market exclusivity, earlier revenue and better health outcomes. Contact: Donna Conroy CEO & Co-Founder [email protected]
32 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES Synergy Therapeutics Synergy Therapeutics has discovered and developed a novel and disruptive way to potently upregulate p53, the “guardian of the genome”, in both wildtype and mutant cancer cells. Our product accesses the intracellular pathways which provides heavy tumor loading; and remains in mouse tumors for 72 hours. The product is tumoricidal, which activates the immune system and holds potential to enable earlier use of ICI compounds. The technology was licensed from the Philadelphia College of Pharmacy/SJU by BusStim, a virtual biotech accelerator. Our product inhibits four anti-apoptotic targets. Synergy’s management team bootstrapped the company with a ~$250,000 investment. Contact: Michael Atkin CEO [email protected] tenXclinical Drug development is expensive and too long due to tedious, redundant and often confusing tasks for clinical trial professionals, clinical staff and Patients. tenXclinical comes from pharma and Google-experienced backgrounds to bring useful tools, clinical co-pilots and learning experiences to help guide anyone in the field leverage AI for daily tasks, document creation and stay compliant with latest industry standards. Contact: Salvatore Campo CEO [email protected] TRIZ Biopharma International TRIZ Biopharma, a New York-based company, has developed a groundbreaking hemostatic agent. Compared to current hemostatics, our hemostatic agent, is biodegradable, biocompatible, absorbs 50 times more blood, stops bleeding 10 times faster and improves wound healing. It has low-cost manufacturing and addresses practical solid needs for the military, healthcare industry and civilian injuries. TRIZ Biopharma’s timeline is to complete a study on swine models and submit an FDA 510K application. The hemostat is protected by three issued patents in the U.S. and Eurasia. The company develops novel pharmaceutical compositions and synergistic combinations with unique pharmaceutical formulations with diverse applications. Contact: Ilya Kleyn, M.D. Chief Medical Officer [email protected] Vasowatch Vasowatch is developing clinical decision support technology to improve the birthing experience for better maternal outcomes. Our initial product is a novel Labor and Delivery technology that provides continuous monitoring of a mother’s risk for postpartum hemorrhage (PPH), excessive blood loss after childbirth, which is the leading cause of maternal deaths and complications globally. Our technology provides up to 10x greater predictive accuracy hours ahead of delivery – saving lives and averting complications. Contact: Stefanie Modri Co-Founder [email protected]
33 BACK TO QUICK LINKS START-UP PRESENTATION PROFILES VITRUVIAE VITRUVIAE is an early stage biotech in New Jersey developing immunotherapies that target sugars and lipids as a new strategy to treat cancer and infectious diseases. Our lead innovation is VIT-GLT3, a tris-specific, T cell engaging immunotherapy to treat pediatric acute myeloid leukemia (pAML), that targets Man9 (a sugar) and PS (a lipid), that are not present on the surface of normal cells and are exclusive signatures of a cancer or pathogen-infected cell. VIT-GLT3 helps the immune system recognize and destroy tumors, regardless of tumor type or genetic mutation, sparing normal cells. Contact: Sonia Sequeira, Ph.D. Founder & CEO [email protected] Zena Therapeutics Zena Therapeutics Inc. is a small molecule CNS drug discovery company spun out of Rutgers University. Our goal is to improve Patient safety and outcomes by designing and developing CNS medications that do not pose life threatening risks if misused or co-used with other substances. Zena’s founders strongly believe that the gap in safety for pharmaceutical medications can be addressed by investing in unique innovations. They have the profound belief that the consequence of medication misuse should never be fatal. Contact: Eileen Carry, Ph.D. Founder & Chief Scientific Officer [email protected] BioNJ’s Talent Services Career Portal is where life sciences applicants go first to find their next job opportunity. Whether posting a job or searching BioNJ’s robust resume database, you are sure to find qualified candidates to meet your hiring needs. User-friendly benefits include: · User-friendly administration backend with enhanced reporting and exportable invoices and billing history · Built-in applicant tracking system · Resume database & advanced filtering for resume search · Resume alerts when a resume matches your criteria · Extended reach through our Partner Network, including ZipRecruiter, Talroo (previously Jobs2Careers), Adzuna, Google for Jobs and LinkedIn · Automatically pull in your job opportunities from your organization’s own job site (scraping) · Enriched company profile page · Spotlight postings by job categories · Increased visibility with banner ads · Internship and fellowship postings at no cost · E-commerce & live chat support BioNJ Members enjoy discounted pricing. Contact Peggy Schell at [email protected] or 609-890-3185 to learn more. Visit www.BioNJTalentNetwork.org today!
34 BACK TO QUICK LINKS HOST SPONSOR TITLE SPONSORS VISONARY SPONSORS THANK YOU TO OUR SPONSORS CATALYST SPONSOR PARTNERING SPONSOR LANYARD SPONSOR AWARD SPONSORS EXHIBIT SPONSORS
35 BACK TO QUICK LINKS SPONSOR PROFILES ADP ADP TotalSource a PEO, or professional employer organization, is an all-in-one, full-service HR outsourcing solution for small and midsized businesses. ADP TotalSource takes on complicated, time-consuming tasks across benefits, HR, compliance, payroll, tax and more — giving you the freedom and confidence to spend more time where your business needs you most. ADP TotalSource makes it simpler and more cost-effective to grow your business. There are more than 900 PEOs in the U.S., representing more than 175,000 businesses and more than 4 million employees. With so many PEOs, it’s essential to research and partner with one that will best meet your needs. Advant-Edge Advant-Edge Solutions of Middle Atlantic is your go-to expert for comprehensive regulated waste management. Our approach ensures compliance, prioritizes sustainability and seeks ways to reduce costs without compromising service quality. With our expertise, you can simplify the complexities that come with managing regulated wastes. We’re not just a service provider; we’re a partner committed to delivering the best solutions tailored to your needs. Trust ASMAI! to transform your waste management experience. Get in touch today to see how we can make a difference for you. Amicus Therapeutics Amicus is a global, Patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. By championing mission-dedication, innovation, performance and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. Ascella Health AscellaHealth is a global health care and specialty pharmacy solutions company, serving Patients, life sciences manufacturers, payers and providers offering a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, AscellaHealth’s best-in-class, Patient-centric approach is built upon proprietary technology processes for novel programs and services to support the launch of specialty medications and proactively address multiple challenges, optimize clinical health outcomes and improve quality of life for this Patient population. Visit www.ascellahealth.com. Ascendia Pharmaceuticals Our experts deliver sophisticated formulations to enhance bioavailability, solubility and stability, while reducing toxicity using GRAS (Generally Regarded As Safe) materials and four proprietary nanotechnologies – NanoSol®, EmulSol®, AmorSol® and LipidSol®. Following formulation selection and optimization, Ascendia can scale-up a development program quickly to cGMP manufacturing of clinical materials. Ascendia’s manufacturing capabilities include sterile, injectables and orally administered dosage forms. Ascendia offers its manufacturing services to biotech and pharmaceutical companies who seek a CDMO partner for their formulations that is steeped in Socratic process as it transitions from a pre-clinical and early clinical development to scale-up, late-stage clinical trials to robust commercial supply. BioBridges At BioBridges, our dedicated and experienced staff of clinical experts manage all aspects of clinical trials for life sciences, pharmaceutical companies, biotech companies and medical device companies. We understand it doesn’t always make sense to have the necessary resources in-house on a full-time basis. And that’s where we come in. Our highly skilled medical consultants serve as an integral part of your team, helping researchers bring innovative products to market efficiently and safely. BOME Pharma BOME Pharma seeks $5M now, another $10M in 2028, alternatively 100% sale to big pharma, to commercialize our world’s first proven safe and effective allergy vaccine for poison oak(PO) and Ivy(PI). The FDA acknowledged Dr. Coifman’s human proof-of-concept experience with a simple, no-obstacles pathway to marketing approval. Total projected cost is $15M from investors + a $5M NJEDA Innovation Evergreen Fund match. With projected manufacturing cost ~$30 per Tx dose or annual booster, selling wholesale for $200, 48M Americans are expected to want the vaccine. We expect annual profit from year 1 reaching >$600M by year five.
36 BACK TO QUICK LINKS SPONSOR PROFILES CFGI CFGI, a leading operationally focused finance and accounting consultancy and M&A advisory firm, provides financial, accounting and pre- and post-closing M&A services to small to middle-market public and private companies and private equity firms. We help our clients address the consequences that their business decisions may have on accounting and financial reporting. We help organizations that are faced with a non-routine transaction, are seeking an interim CFO, need improved business intelligence tools, require GAAP or SEC advice, or just need an experienced team who can see them through crunch times.. Datasite DataSite is a Virtual Data Room (VDR) that optimizes the due diligence process by transforming the traditional paper data room into a secure, online data room, accessible via the Internet at any time of the day or night, globally. A VDR is a secure and highly efficient method for sharing critical business information used in electronic due diligence in M&A advisory, transfer of small business ownership when selling a company, document warehousing, mergers and acquisition due diligence, succession in family business, or when buying a business, filing for chapter 11, liquidation analysis, financial and corporate debt restructurings and preparing exit strategies. DLA Piper DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. We strive to be the leading global business law firm by delivering quality and value to our clients. We deliver consistent services across our platform of practices and sectors in all matters we undertake. Our clients, among them life sciences clients, range from multinational, Global 1000 and Fortune 500 enterprises to emerging companies developing industry-leading technologies. For more information, contact Emilio Ragosa at [email protected]. EisnerAmper EisnerAmper’s Life Sciences Practice professionals have the expertise, resources and relationships to assist both public and private life sciences companies bridge the gap between business and science. In addition to traditional tax and accounting services, EisnerAmper assists our life sciences clients with outsourcing accounting solutions, technology, corporate finance and IPO readiness services. For more information, visit us online at www.eisneramper.com/life_sciences and explore our thought leadership resource library at www.eisneramper. com/knowledge-center. FedSprout Fedsprout is a consulting firm helping businesses develop their strategy and roadmap for obtaining government funding. We assist clients with proposal writing and government project reporting. GenVault GenVault is a highly secure and comprehensive commercial biorepository located outside of Philadelphia, PA. The state-of-the-art facility is purpose-built to store and transport large collections of biological materials, laboratory chemicals, infectious and non-infectious materials, and high-value equipment. GenVault caters to a broad spectrum of clients, including academic research institutes, pharmaceutical companies, biotech firms and government agencies. Grant Thornton Grant Thornton LLP, the U.S. member firm of Grant Thornton International, is one of the six global accounting, tax and business advisory firms. Grant Thornton LLP provides a level of service that fosters the individual service relationships our clients expect. For more information, contact George Serafin at [email protected] or 732-516-5580. Jersey City Economic Development Corporation The Jersey City Economic Development Corporation (JCEDC) is a private, nonprofit 501 (c) (3) corporation created in 1980. The Mission of the JCEDC is to promote and facilitate economic development throughout Jersey City. JCEDC serves the business community of Jersey City by: Assisting businesses, especially small businesses, with technical assistance and flexible financial programs that create and retain employment opportunities; administering programs that stimulate neighborhood economic development; working with government to coordinate existing economic development efforts and focus resources for maximum impact. Marketing Jersey City as a premier destination to the leisure and business traveler.
37 BACK TO QUICK LINKS Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. J.P. Morgan J.P. Morgan Life Sciences bankers are dedicated to delivering financial solutions tailored to your needs. From early-stage start-ups to multinational corporations, we understand the unique challenges life sciences companies face at every stage of their life cycle. The pace at which life sciences companies move from proof of concept to commercialization is accelerating, and J.P. Morgan offers a unique platform with which your company can grow. Our national footprint enables us to provide access to vital industry networks and leverage firm-wide expertise while helping guide your company as it navigates the regulatory environment and FDA approval process. For more information, contact Kathleen Addison, Executive Director – Life Science at [email protected] Marcum LLP Marcum LLP is a national accounting and advisory services firm dedicated to helping entrepreneurial, middle-market companies and high net worth individuals achieve their goals. Our business philosophy and proven track record of successfully managing change, provide us with a deep appreciation of the challenges that life sciences and biotech industry management teams face, and positions us well to help our clients achieve success as opportunities and challenges emerge. Marcum offers a complete spectrum of accounting and advisory services, with specialized expertise for both privately held and publicly registered companies. The firm also provides a full complement of technology, wealth management, executive search and staffing services. Merck & Co. Merck’s success stems from translating research into life-saving medical breakthroughs. From Merck’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we’ve become an industry leader in bringing innovative new medicines to Patients. Approximately half of our pipeline is attributable to acquisitions, alliance partnerships and patents with our team executing 76 significant business development transactions in 2023. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at www.merck.com/licensing. Middlesex County The Office of Business Engagement (OBE) is the key connector and partner for market-leading companies and innovative entrepreneurs seeking to relocate, expand or start-up in Middlesex County, NJ. With a focus on enhancing the County’s nationally recognized ecosystem for life sciences, food innovation and autonomous technology industries, the OBE, together with the business community, is charting the County’s path in the next normal. The OBE offers assistance in a range of areas including workforce development, site selection and the entitlement process, and facilitates introductions to key local leaders to enable a seamless transition, operation and sustainable growth. Morgan Lewis With more than 400 lawyers who focus on the life sciences industry, Morgan Lewis has one of the most comprehensive practices in this area. We are unsurpassed in our global understanding of the business, regulatory, intellectual property, litigation and related issues that our clients face along the product life cycle, from innovation and emerging business issues, through research and development, regulatory approval, product reimbursement, marketing and distribution, to fraud and abuse, product liability and intellectual property litigation, to mergers and acquisitions, collaborations and outsourcing. The breadth of our industry clientele includes large and mid-size pharma and biopharma, emerging biotechnology, medical device, food and nutritional supplements, wholesalers and distributors, research and scientific institutions and venture capital and private equity funds focused on the industry. New Jersey Economic Authority The New Jersey Economic Development Authority (NJEDA) grows the State’s economy and increases equitable access to opportunity by supporting high-quality job creation, catalyzing investment and fostering vibrant, inclusive community development. NJEDA works in partnership with a diverse range of stakeholders to implement programs and initiatives that improve quality of life, enhance economic vitality and strengthen New Jersey’s long-term economic competitiveness. SPONSOR PROFILES
38 BACK TO QUICK LINKS New Jersey Health Foundation New Jersey Health Foundation, a not-for-profit corporation, along with its affiliates Foundation for Health Advancement and Foundation Venture Capital Group support the development of health-related research, education programs and start-up ventures in New Jersey by providing leadership and guidance as well as financial, technical and administrative support to researchers at Cooper University HealthCare, Hackensack Meridian Health, Kessler Foundation, Princeton University, New Jersey Institute of Technology, Rowan University, Rutgers University and Stevens Institute of Technology through its Research Grant Program, Innovation Grant Program and impact investments. For more information, call 908-731-6605. New Jersey-Israel Commission The New Jersey-Israel Commission was established in 1989 to promote the development of trade, culture and educational exchanges; encourage the development of capital investment and joint business ventures; and foster a spirit of cooperation between the citizens of the State of Israel and the State of New Jersey. The New Jersey-Israel Commission was placed under the purview of the Department of State in July, 2007. Prior to this, the Commission came under the New Jersey Commerce, Economic Development & Tourism Commission (which is now the New Jersey Commerce Commission). New Jersey Commission on Science, Innovation and Technology (CSIT) The Commission on Science, Innovation and Technology (CSIT) (www.njeda.gov/csit) is responsible for strengthening the innovation economy within the State, encouraging collaboration and connectivity between industry and academia, and the translation of innovations into successful high-growth businesses. CSIT manages a robust suite of grant programs ($25K - $250K) for innovation intensive startups and hosts the ResearchWithNJ portal https://www.researchwithnj.com/ providing insight into groundbreaking research being conducted at New Jersey universities. Princeton Innovation Center BioLabs Princeton Innovation Center BioLabs, a premier incubator for technology and life sciences start-ups in New Jersey, is a 30,000 squarefoot facility that offers wet and dry labs, private offices and open coworking space for startup companies with transformative technologies that are interested in a collaborative environment. The members of Princeton Innovation Center BioLabs have access to our shared lab equipment, EH&S and hazardous waste services and a convenient purchasing platform. We also offer educational events and networking opportunities for entrepreneurs and innovators. ThermoFisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Withum Withum is a forward-thinking, technology-driven advisory and accounting firm committed to helping life sciences companies navigate the fast-paced, dynamic environment regardless of their current life cycle or stage of development. With offices in major cities and financial centers across the country, and as an independent member of HLB, the global advisory and accounting network, we support businesses across the country and from around the world. We offer innovative solutions to help public and private life sciences companies achieve their goals. Get to know us at www.withum.com/lifesciences or contact Taryn Bostjancic at [email protected] or (732) 964 9319 for more information. SPONSOR PROFILES
39 BACK TO QUICK LINKS ATTENDEE LIST Name Job Title Company Revital Abraham Elnekave Co-Founder & CEO Markable Kathleen Addison Executive Director, Life Science JPMorgan Chase Bank NA Pavlo Ageyev Partner Centri Business Consulting Arnon Aharon CEO AlonBio Ltd. Aqil Ahsan CEO & Founder Kognitic Alejandro Aivar Partner IDR (Insights Driven Research) Akin Akinsanya Head, High Growth Acceleration Invest Newark Valon Alaj Vice President JPMorgan Chase Bank NI Michael Albert Associate New Enterprise Associates Tor Alden CEO Sympfiny Scott Alpizar Principal Emerging Innovations Consulting Roee Amit Chief Technology Officer Benevira Avigail Anavi Owner & Founder Avimeduza Astrid Androsch CEO Quantum Bio Tek Siddhesh Angle President & CEO Regenosine Andrew Apicello Chief Business Officer Sentauri Joseph Armstrong Chief Medical Officer TCG GreenChem Patty Arnold Special Assistant New Jersey Israel Commission Deepa Arora CEO Clinexel Life Sciences Pvt Ltd Monika Athwal Sr. Product Officer Innovation Programs New Jersey Economic Development Authority Michael Atkin CEO Synergy Therapeutics Naomi Baer Business Developing Consultant MilliporeSigma Divyansh Bajpai Co-Founder DTxPlus Shikha Bajpai Co-Founder DTxPlus Albert Baker Corporate Director, LS Innov. and Tech Transfer Hackensack Meridian Health Kalindi Bakshi Economic Development Specialist Office of Business Engagement, Middlesex County Andy Bala CEO & Founder Delphine Diagnostics Vinodh Balaraman CEO & Co-Founder KolateAI Pharma Tech Erika Ballo Senior Manager EisnerAmper Michael Baran Principal Pfizer Cameron Bardliving Business Development Manager Cytiva Josh Barer CEO Hibiscus Capital Management Jennifer Barnes Client Relationship Manager Grant Thornton Florence Baron Director, Development Jersey City Economic Development Corporation Paul Barone Chief Business Officer Adolore Biotherapeutics Rachel Barreto Regional Director Datasite Jay Batchu Senior AnalystEIR Xontogeny Mark Baum Angel Investor JumpStart NJ Angel Network Bob Bell Director, ERP Archer Insights Joshua Benig Head, Business Development IDR (Insights Driven Research) Avishai Ben-Tovim CEO MDI Health Lex Beresnev Chief Technology Officer Lumacell Systems Josh Berliner Executive Director New Jersey Israel Commission Jacqueline Berman Partner Morgan Lewis John Berrios Consultant Self-employed Gunjan Bhardwaj CEO Partex NV Millan Bhatt GMP Manufacturer Molecular Pharmagroup
40 BACK TO QUICK LINKS ATTENDEE LIST Name Job Title Company Jay Bhatti Managing Director 49 Alpha Sukhada Bhave Alliance Manager, Business Development Columbia Technology Ventures, Columbia University Leena Bhoite Senior Alliance Manager University of Maryland Sarindr Bhumiratana Chief Scientific Officer & Co-Founder EpiBone Orli Biger CEO, ARC US Liberty Science ARC HealthSpace 2030 Raymond Birge Professor Targeron Therapeurtics Doug Bixby Sr. Vice President Alliant Melina Blees Site Director BioLabs Philadelphia Robert Bloder Board Advisor/Chief Business Officer Ascendia Pharmaceuticals Lars Boesgaard CFO PDS Biotechnology Corporation Emmanuelle Bommier Head, Business Development North America Minaris Regenerative Medicine USA Greg Bosch Chairman & CEO Panavance Therapeutics Taryn Bostjancic Partner, Practice Leader, Life Sciences Services WithumSmith+Brown Mark Boulding Executive Vice President & Chief Legal Officer PTC Therapeutics Lyric Boyle Director, Business Development Altasciences Christopher Brandes Partner CFGI Nicole Brenna Business Development Director Cromos Pharma Glen Bressner Managing Partner Activate Venture Partners Jarred Bressner Principal Activate Venture Partners Gabe Brun Sr. Director, Business Development Neuroscience Johnson & Johnson Gerry Brunk Managing Director Lumira Ventures Tyler Bryk Head, AI PTC Therapeutics Benito Buksh Doctoral Student Princeton University Marc Burel President Trinity Orthopedics and Diagnostics Laurie Burlingame Partner Morgan Lews & Bockius Samuele Butera President, Johnson & Johnson Innovative Medicine Johnson & Johnson John Callaghan Chief Financial Officer ViCardia Therapeutics Marshall Calman Co-Founder & Principal LeaderStrong Salvatore Campo Co-Founder & CEO tenXclinical Thomas Cantwell Partner Marcum Eileen Carry Chief Scientific Officer Zena Therapeutics Tina Caruana Director, eClinical Solutions Medrio Mario Casabona Founder & CEO Casabona Ventures Sandy Castor Department Head Office of Business Engagement, Middlesex County Kim Cato Vice President, Information Technology Thermo Fisher Scientific Cortney Cavanaugh New Ventures and Licensing Associate Princeton University Sheila Chandonnet Member Mid Atlantic Bio Angels Prathik Chandrasekaran Vice President, Life Science JPMorgan Chase Bank NA Karen Chandross Head, Scientific Relations & Initiatives, NA Sanofi William Chelak Vice President, Sales Hetero USA Juliet Chin-Hart CEO & Founder Hart & Chin Laura Chittick Managing Director JPMorgan Chase Bank NA Jonathan Chow Business Development Manager Covar Pharmaceuticals Kwok Chow President Covar Pharmaceuticals Mohan Chukkapalli Principal Inizio Tinchun Chun Professor, Biological Sciences Seton Hall University
41 BACK TO QUICK LINKS ATTENDEE LIST Name Job Title Company David Chung Chief Business Officer Avistone Biotechnology George Clarke Project Director Investment Reports Adam Closson Investor Chemical Angel Network John Coelho Senior Advisor, Life Sciences Sector New Jersey Economic Development Authority Rachel Cohen Business Development Officer Choose New Jersey Daniel Cohen CEO Lumacell Systems Steven Cohen Partner, Chair Emerging Business & Tech Practice Morgan Lewis Robert Coifman CEO BOME Pharma Robert Coifman CEO BOME Pharma Max Colbert Associate Medical Excellence Capital Elaina Coletta Managing Director CFGI Nicholas Collette Co-Founder Celleqore Bill Comtois Associate Partner IBM Joseph Conrad Senior Technology Analysis & Marketing Specialist National Cancer Institute Donna Conroy CEO & Founder SciMar ONE Joe Cordasco Vice President, Sales & Marketing Synergistix Kara Costello Manager Grant Thornton Gidon Coussin Co-Founder & Vice President, Business Development Dimer Health Kathleen Coviello Chief Economic Transformation Officer New Jersey Economic Development Authority Bridget Coyne Director, Business Development, BioA Lab Altasciences Katelyn Crowley-Lum Business Development Executive WithumSmith+Brown Gina Cuniere Vice President, Partnerships The Grovery Neal Davies Sr. Vice President Toppan Merrill Analicia De Los Angeles Product Manager Kognitic Brian DeBeer Chief Operating Officer Allele Capital Partners Michael DeFeo Vice President, Life Sciences JPMorgan Chase Bank NA Nicholas DeLorenzo Business Development Associate Minaris Regenerative Medicine USA Alma DeMetropolis Managing Director JPMorgan Chase Bank NA Michael Demurjian CEO Aspargo Laboratories Adam Demurjian Director, Business Development Aspargo Laboratories Ani Demurjian Director, Marketing Aspargo Laboratories Vivian Denkins Banking Associate, Life Sciences JPMorgan Chase Bank NA Nick DePhillipo Chief Operating Officer Mechano Therapeutics Bill DeStefano Vice President, Life Science Practice Marsh Krishna Devarakonda Chief Scientific Officer 6S PHARMA LLC Annie Devine Sr. Vice President Marsh Mary Diamond Vice President, Regional Sales Fisher Scientific Company Veronica DiCamillo Counsel Morgan Lewis Mike DiCesare President ZEPHYRx Cuong Do Executive Chairman Seneca Therapeutics Aruna Dontabhaktuni Founder & CEO PharmaPro Consulting Jared Downard Business Development Manager CMIC CMO USA Michael Duffy Executive Director, Technical Services CHA Steve Dyer Managing Member SRD Capital Management Zach Eisenberg Sales Consultant TriNet
42 BACK TO QUICK LINKS ATTENDEE LIST Name Job Title Company Sandra Elliott Vice President, Chief Innovation & Commercialization Officer Hackensack Meridian Health Saleem Elmasri Managing Partner Titan Advisory Services Mark Esposito Vice President, R&D KayoThera Mahako Etta Program Manager NJ Commission on Science Innovation and Technology Dawn Fallon Founder & CEO New Dawn Communications Tricia Fama Chief Operating Officer Element Six Creative Group Jim Fan Co-Founder, Interim CEO & CSO Somnia Therapeutics Boris Farber CEO TRIZ Biopharma International Matt Fazelpoor Journalist NJBIZ Eric Feerst Project Manager BOME Pharma Deborah Fenster Senior Director, Business Development ParadigmIT Clinical Trial Services Rossana Ferrara-Pontoriero Vice President, Business Development & Alliance Management Scynexis Rachel Fill Executive Account Director, Business Development Thermo Fisher Scientific Robert Fiorentino Life Science Practice Lead Partner Marcum Tony Fiori Senior Managing Director Manatt Health Nicholas Fiorino Account Manager Fisher Scientific Company Greg Fisher Manager, Operations Effectus Group Seth Flaum Partner Wilson Sonsini Goodrich & Rosati Charley Ford Senior Commercial Officer Consulate General of Canada in New York - Ontario Trade & Investment Office Sarah Frey Laboratory Equipment Representative Thermo Fisher Scientific Ashley Friedman Managing Director Signet Healthcare Partners Sarah Fuller Vice President, Head, Business Development North America Kyowa Kirin Mitchell Fullerton Sr. Business Development Associate Columbia University Steven Fulop Mayor Jersey City Akihiro Furukawa Director, Research & Technology Search & Evaluation Daiichi Sankyo Takeru Furuya Principal Xontogeny Stephen Gacheru Vice President Frontage Laboratories Jose M. Galarza CEO TechnoVax James Gale Managing Director Signet Healthcare Partners Tina Garyantes Chief Operating Officer Linnaeus Therapeutics Nayan Ghosh Head, Life Sciences & HealthTech Marwood Group Adit Ghosh Associate NEA Sam Giannakoulias Chief Technology Officer Sentauri Bob Gilkin Sr. Vice President, Trade and Specialty Strategy AscellaHealth Ian Gillan Regional Director Datasite Gianandrea Giochetta Director of Strategy Clinical Services International Majory Giordani-Petion Vice President, Life Sciences JPMorgan Chase Bank NA Rachel Gisser Marketing Manager WithumSmith+Brown Igor Gitelman - - Kevin Givechian Chief Scientific Officer Ascent Bio Amanda Goceljak Partner Morgan Lewis Neil Goldstein Chief Scientific Officer SkunkWorx Bio
43 BACK TO QUICK LINKS Name Job Title Company James Golubieski President New Jersey Health Foundation/Foundation Venture Capital Group John Gonzaga Associate, Life Science JPMorgan Chase Bank NA Tom Gordon Managing Director Silicon Valley Bank Boris Gorelik Vice President, Business Development Kamada Frank Grams Chief Clinical Officer Partex NV Jason Gray Head, Investment Team Pritzker Vlock Capital Management Walter Greenblatt Managing Director Walter Greenblatt & Associates Andreas Grill President & CEO DepYmed Elliott Gruskin CEO Azome Therapeutics Fay Guan BD Executive II GenScript ProBio Jonathan Guarino Sr. Vice President & Chief Financial Officer Soligenix Manasa Gummalla Vice President, Startup Banking JPMorgan Chase Bank NA Jim Gunton Managing Partner Tech Council Ventures Pankaj Gupta Search & Evaluation Lead, Inflammation & Immunolog Pfizer Michael Hadjiloucas Partner EisnerAmper Jaap Haemers Investment Manager NLC the European Healthtech Venture Builder William HaGamman Consultant GenHenn Capital Scott Hansen Director, BD & Alliance Management Bausch Health Lenzie Harcum Director, NJ Bioscience Center New Jersey Economic Development Authority Andy Harlan Executive Director, Asset & Wealth Management JPMorgan Chase Bank NA Claire Harnett Associate Banker JPMorgan Chase Bank NA Dov Hass Vice President, Head, Genetic Medicine Business Development Regeneron Mark Hatton Chief Medical Officer TelomEye Mark Hatton Chief Medical Officer TelomEye Pharmaceutical Corporation Jenna Hebert Senior Venture Associate RA Capital Eric Heil Managing Partner Medical Excellence Capital George Heinrich Vice Chair & CEO New Jersey Health Foundation/Foundation Venture Capital Group Shahram Hejazi CEO & Managing Director BioAdvance Pete Henderson Sr. Vice President, Client Services BioBridges Francisco Heredia Director, Business Development Tedor Pharma Services Charles Higgins Managing Director Centri Business Consulting Bethany Hills Partner DLA Piper Jake Hindelong Managing Director New Harbor Venture Partners christian hinrichs CEO Scarlet TCR Caroline Hodge CEO Dimer Health Paul Hoffman President & CEO Liberty Science Center Dalton Holland Major Accounts Executive Advant-EDGE Solutions of Middle Atlantic Donald Holland Vice President Advant-EDGE Solutions of Middle Atlantic Gary Hom Retired from Merck - Harvey Homan CEO & Co-Founder METASTX Takeshi Hondo Director, Global Open Innov, Corp Strategy Mitsubishi Tanabe Pharma America William Houston Partner Eldari Bio Paul Howard Senior Director, Public Policy Amicus Therapeutics Guanghui Hu CEO Ribogenics Jim Huang CEO & Founder Ascendia Pharmaceuticals ATTENDEE LIST
44 BACK TO QUICK LINKS Name Job Title Company Natalie Hudson-Smith Professor of Chemistry Saint Peter's University James Hussey CEO Seneca Therapeutics Randall Hyer CEO Merlin Biotech Ashok Illapakurthy CEO 6S Pharma LLC Eunju Im Principal Manager, Global BD Amyloid Solution Brian Imszennik Director, Venture Investments Johnson & Johnson Joseph Incelli Senior Finance Manager, Venture Investments Johnson & Johnson Michael Ingber Chief Medical Officer LiviWell Sho Islam Division Head, Life Sciences & Food Innovation Office of Business Engagement, Middlesex County Jacqueline Iversen Chief Clinical Officer Sen-Jam Pharmaceutical James Iversen CEO Sen-Jam Pharmaceutical Madhalasa Iyer Student Princeton University Manoj Jadhav Founder & CEO ISHA Therapeutics Varsha Jain Computational Chemist Iktos Joanne Jiang Chairman & CEO LeaderMed Group Zuwei Jin Vice President, Business Development NA Lisure Technology Co Michael Johnson President New Jersey Innovation Institute Kyle Johnstone Account Executive Corporate Traveler Sophie Jones Managaing Director, Corporate & Investment Bank JPMorgan Chase Bank NA David Jones Business Development Sannova Analytical Venkatraman Junnotula Founder & CEO QRD Pharma Ashley Kalinauskas CEO Torigen Aniket Kaloti Senior Managiang Director Leerink Partners Avi Kamelhar CEO Axella Research Rashida Karmali CEO &President Tactical Therapeutics Steven Karuppan Business Partnership Executive Mayo Clinic Josh Kaufman Partner DLA Piper Sharandeep Kaur Optometric Technician America's Best Syed Kazmi CEO Jubilant Therapeutics Michael Keane Founder Aspicio Therapeutics Gilead Kedem Co-CEO PolyCypher Health Frances Keel Senior Project Lead New Jersey Economic Development Authority Nancy Kelley President & CEO Nancy J Kelley & Associates Michael Kempin Principal Stantec Nitin Khanna CEO Archer Insights Daniel Khomenko Head, Operations IDR Insights Driven Research Maarika Kimbrell Partner Morgan Lewis Susan Kindya Regional Director Datasite James Kirwin Chief Operating Officer, Head Development Operations SFA Therapeutics Joseph Kiszka Business Development Director Genesis Biotechnology Group Patricia Kitchen CEO Benevira Merom Klein Principal Courage Growth Partners Ilya Kleyn Chief Medical Officer TRIZ Biopharma International Krissy Klinges Stehle Regional Director Datasite Merika Koday Principal Accelerator Life Science Partners Mark Kolb Partner Tech Council Ventures Simon Koo Director, Financial Valuation Marshall & Stevens ATTENDEE LIST
45 BACK TO QUICK LINKS Name Job Title Company Sven Krause President North America Partex NV Rahul Krish Vice President, Business Development, Research Part Ibis KJ Kulik Assistant Vice President Scheer Partners Manish Kumar President Aeklvya Advisors Patrick Kumm Partner Atinum Investment Brenda Kurnik Partner Robin Hood Ventures Demetrios Kydonieus Founding Partner Biotech Value Advisors Lina Lahoz Associate Director, Portfolio Teva Pharmaceuticals Pablo Lapuerta CEO & Founder 4M Therapeutics Andrew Latham Executive Director, Enabling Technologies, BD &L Merck & Co. Philip Laut Vice President, Head of US Sales, BD & Operations Iktos john lavery Senior Vice President Fulton Bank Cathy Lawler CEO & President TAB of Central NJ (White Eagle Partner) Wendy Lazarus Principal WML Public Affairs Guy Le Houillier General Manager Domain Therapeutics NA Emer Leahy President & CEO PsychoGenics Lisa LeCointe-Cephas Partner DLA Piper Curtis Lee Senior Product Officer, Venture Programs NJEDA, Venture Helen Lee Research Scientist and Asst. Director Stevens Institute of Technology Alan Leeds Partner Morgan Lewis Meenal Lele CEO Hanimune Therapeutics Joe Leone Executive Vice President SST Corproation Joel Levin Managing Partner TBP&L Invest Orly Levitan Vice President, Partnerships & BD Pragma Bio Jack Levitt Co-Founder & Principal LeaderStrong Michael Li Partner Mid Atlantic Bio Angels Amy Liao CEO Couragene Inc. Santo Libero Senior Safety Specialist Fisher Scientific Company Mike Liccardo Vice President, Corp. Dev. & Chief Financial Officer ShareVault Alan Lieber Healthcare Executive Health Care Navigator Abraham Lin CEO Orbits Oncology Bill Liu CEO FrontAim Biomedicines Xuan Liu Associate Professor New Jersey Institute of Technology Tommy Lobben Manager, Global Community Impact North America Johnson & Johnson Joe Lobdell Architect Flad Architects Stuart Loesch President Intrommune Therapeutics Serge Loncar Investor Jumpstart NJ DAVID LOPEZ CEO Advent Therapeutics Michael Losch Chief Financial Officer Signum Biosciences Livia Lu Senior Business Development Manager Charles River Laboratories Shan Lu BD FrontAim Biomedicines Gary Lynch Managing Partner Uncertainty Advantage Corp. Will Ma Founder & CEO HopeAI Jaseem Mahmmdla Chief Technology Officer & Co-Founder Kognitic Nancy Maira Business Operations SSI Strategy Gene Mancino Partner Mancino Burfield Edgerton ATTENDEE LIST
46 BACK TO QUICK LINKS Name Job Title Company Jason Mancivalano Executive Director, Asset & Wealth Management JPMorgan Chase Bank NA Viraj Mane Co-Founder Lactiga Jessica Manning Project Director Stantec Gregory Mario CEO TAXIS Pharmaceuticals Melissa Marschall Account Manager MilliporeSigma Jim Martin Sr. Vice President, Business Development Ipsos John Martinson Chairman Martinson Ventures Masuga Masuga Founder & President Jessica Masuga Consulting Ashley Matarazzo Principal Account Executive Corporate Traveler Mark Maxwell Executive Director Business Development SK pharmteco Rosemary Mc Fadden Chair - Board of Trustees Jersey City Economic Development Corporation Dean McAlister Executive Vice President Inizio Darcey McDermott Chief Marketing & Communications Officer AscellaHealth Rod McGlashing Data Science Subject Matter Expert Medrio Taggart McGurrin - - Tim McGurrin Vice President, Finance & Controller Enalare Therapeutics Scott Megaffin President & CEO Adiso Therapeutics Rikin Mehta Co-Founder Lactiga Edward Messick Chief Techonology PolyCypher Health Robert Millar President & Director EmphyCorp Alita Miller Chief Scientific Arrepath Mohammad Mir Postdoctoral Researcher Stevens Institute of Technology Stefanie Modri Co-Founder Vasowatch Ameena Moghe Founder & CEO NanoInk Imaging Ann Mohamadi CEO Sapphire Associates Christopher Montalbano President MIDI Product Development Corp. Rebecca Moore Marketing Director, Pharma AscellaHealth Jennifer Moore Small Business Director Jersey City Economic Development Corporation Olivier Morali Owner Omicron Capital Chris Mortko Associate Vice President, Head, HQ Search & Evaluation Merck & Co. Daniel Motto Chief Operating Officer Enalare Therapeutics Bibhash Mukhopadhyay Managing Partner Sound Bioventures Lauren Murdza Partner DLA Piper Beth Ann Murphy Graduate Director Rutgers, Professional Science Master's Program Carolyn Myers Principal BioEnsemble Saiprakash Nadar Managing Director Syneos Health Jon Napoli Account Executive ShareVault Mahesh Narayanan Managing Partner Neuvation Ventures Bakela Nare Consultant Self Employeed Shawn Nicholas Business Development Director Fortrea Jesse Nicholson Director, Key Accounts - Biotechnology Segment Fisher Scientific Company Adam Nomer Business Development Manager W. R. Grace & Co. Hanne Noyen Scientific Liaison Manager Ziphius Dennis O'Dowd CEO AGelity Biomechanics Corporation Yasin Oduk CEO NanomediGene Jacques Ohayon President Visual Intelligence ATTENDEE LIST
47 BACK TO QUICK LINKS Name Job Title Company Keiko Oishi President & COO CMIC Group Kristine O'Keefe Executive Director - Private Bank JPMorgan Chase Bank NA Brynna O'Leary Associate, Life Science JPMorgan Chase Bank NA Jason Oliver Senior Director, Business Development Ascendia Pharmaceuticals Nancy Ondovik Senior Director, New Company Creation Johnson & Johnson Mike Orangers Sales Representative Thermo Fisher Scientific Miriam Oron CEO DermAb.io Akan Oton Managing Director Barings Alternative Investments Rob Ott Principal Consultant Ott Management Solutions John Otten Director, Partnerships Techstars Georgia Owusu Associate, Life Science JPMorgan Chase Bank NA Pablo Oyler Castrillo Doctoral Student Princeton University Alexander Pachman Manager Venture Programs New Jersey Economic Development Authority Oriana Papin Zoghbi CEO & Co-Founder AOA Dx Ajit Parhi CSO TAXIS Pharmaceuticals Kirthika Parmeswaran President & CEO Vital Start Health Adityavikram Pathak CEO Pathak Technologies Shyam Pattabiraman Chief Financial Officer Jubilant Therapeutics Lorenzo Pellegrini Managaing partner Hatch BioFund John Pennett Partner, Technology & Life Sciences EisnerAmper Andrew Peranick Director, Business Development & Corporate Strategy Adiso Therapeutics Charlie Perperidis Co-Founder Starton Therapeutics Mathieu Petitjean CEO PHARMANEST Dean Petkanas CEO Neuropathix. Eusebio Pires Sr. Manager, Technology Marketing & Business Dev. Rutgers, The State University of New Jersey David Polinsky Co-Founder & Chairman Clinical Trials Sicco Popma Chief Scientific Officer Accelerated Biosciences Mary Potasek President Simphotek Jeff Prall Business Development Director Intelligencia AI Darpita Purohit Sr. Engagement Manager Syneos Health Brian Pusch Secretary, Treasurer, BOD Member Xiconic Pharmaceuticals Donovan Quill Executive Vice President, Business Development Growth & Strategy AscellaHealth Thomas Quinn Private Wealth Advisor Goldman Sachs Bradford Quosig Growth & Client Engagement Calcium+Company Dana Rabinovich CEO OphtiMed Rx Bill Ragatz President & CEO Sentrimed Gayathri Raghupathy Vice President Kognitic Emilio Ragosa Partner & Managing Partner DLA Piper Danny Raie Senior Director, Business Development Altasciences SANGEETHA RAMSAGAR Founder & CEO Kronos Health Warren Rappleyea Marketing Liaison Office of Business Engagement, Middlesex County Mark Ravera Founder & Chief Business Officer NanoInk Imaging Raven Reddy Vice President, Founder Strategy and Operations Cure.Bio James Reynolds Principal Marcum Alex Richter Executive Director & Head, SciTech Innv. Hub Liberty Science Center Blake Roberts Partner Centri Business Consulting ATTENDEE LIST
48 BACK TO QUICK LINKS Name Job Title Company Laetitia Rodes Head of Business Development, East Coast Lonza Biologics Michelle Roemer-Schoen Senior Event & Operations Manager Princeton Innovation Center BioLabs Roelof Rongen CEO Adolore Biotherapeutics Kristin Roosevelt Industry Director Fisher Scientific Company Michael Rose CEO PERMEVO Wayne Rowe Academic Partnerships Program Lead Sanofi Elizabeth Rowley Director, Operations Princeton Innovation Center BioLabs Michael Russo Partner CFGI Richard Russo President & CEO Endomedix Laura Ruth Senior Sales Consultant TriNet Zohaib Saeed Director, Acquisitons Johnson & Johnson Adam Salamon CEO &Founder Pression Larry Samilow Co-Founder & Managing Director Verve Group Consulting Matt Sampson Senior Manager WithumSmith+Brown Jessie Santana Vice President, Life Sciences and Healthcare Services JPMorgan Chase Bank NA George Santo Vice President, Life Sciences JPMorgan Chase Bank NA David Sapirstein Senior Manager, Business Development SK Pharmteco Ihor Sawczuk President Academics, Research & Innovation Hackensack Meridian Health Lindsi Scanlan Partner CFGI Mary Schaheen President Prevail Partners Jay Schiff Co-Founder & CEO Addinex Technologies Ryan Schipke Director, Transacions CVMR Johnson & Johnson Steve Schluter Managing Director Marsh Eric Scholl Managing Partner Matchbook David Schwartz Partner Morgan Lewis Fizza Seehra Strategic Market Director Johnson & Johnson Michael Seiden CEO Gladius Therapeutics John Seman CEO Canget BioTekpharma Chris Senanayake CEO & Chief Scientific Officer TCG GreenChem Sonia Sequeira CEO Vitruviae Craig Serio Founder & CEO Thread Bioscience Squire Servance Managing Partner Syridex Bio Jim Seymour Regional Business Development Manager Biotechnology Innovation Organization Aalap Shah President & CEO Fedsprout Shreyas Shah Research Scientist Nokia Bell Labs Mandar Shah Chief Operating Officer & Co-Founder Prima Innovations Gary Shangold CEO InteguRx Therapeutics Tara Sharif Managing Director ThinkEquity Melindah Sharma Managing Director, Life Sciences Manatt Health Pragati Sharma Associate Director Rutgers, The State University of New Jersey Keren Shavit Co-Founder & Chief Operating Officer Sweetch Health Judith Sheft Executive Director New Jersey Commission on Science, Innovation & Technology Nicholas Shubin CEO NemaGen Discoveries Ryan Signora Marketing Coordinator Morgan Lewis Diego Silva CEO Vaxine Max Simonovsky Founder & CEO Soapy - Hand Hygiene Compliance ATTENDEE LIST